US.JNJ · Johnson & Johnson

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.8,
      "details": {
        "atrPct": 2.5673519440484736,
        "turnoverUsdM": 1703.82829144262,
        "liquidityPoints": 0.8,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.JNJ",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 242.6844,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 2,
        "rsi_score": 1,
        "macd_score": 1.5,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1,
      "stop_loss_percent": 5.1,
      "take_profit_price": 268.611,
      "target_multiplier": 1.6,
      "technical_strength": 1.38,
      "take_profit_percent": 5
    },
    "positionPoints": 1.8,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 5.134703888096947,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 53,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 52,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 1
  },
  "market": {
    "ma20": 258.125,
    "ma50": 244.6744,
    "close": 255.82,
    "prevClose": 265.53,
    "avgVolume20": 8090278,
    "volumeRatio": 0.82,
    "changePercent": -3.66
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 1,
    "details": {
      "ret_5d": -0.013306514957631688,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 1,
      "vcp_bonus": 0,
      "vol_ratio": 0.8239747423324496,
      "ret_points": 0,
      "vol_points": 0,
      "range_ratio": 1.0347817862817394,
      "volat_points": 0,
      "day_range_pct": 0.023292900348178366,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 1,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 53,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 4.4,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 88,
        "contribution": 4.4
      },
      {
        "raw": 9.2,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 46,
        "contribution": 9.2
      },
      {
        "raw": 7.2,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 48,
        "contribution": 7.2
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 7,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 70,
        "contribution": 7
      },
      {
        "raw": 18.2,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 60.67,
        "contribution": 18.2
      },
      {
        "raw": 4,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 40,
        "contribution": 4
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "避免",
    "result": 52,
    "details": [
      "基本面分析總分: 4.4/5分",
      "資金流分析總分: 9.2/20分",
      "市場環境分析總分: 7.2/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 7/10分",
      "技術信號分析總分: 18.2/30分",
      "情緒分析: 4/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 4.4,
      "資金流": 9.2,
      "市場環境": 7.2,
      "情緒分析": 4,
      "技術信號": 18.2,
      "風險管理": 7
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "優秀",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.2,
          "epsPoints": 0.75,
          "roePoints": 0.75,
          "debtPoints": 0.5,
          "marginPoints": 0.6,
          "turnoverUsdM": 1703.82829144262,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0.4,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 0.8,
          "mfiPoints": 1.6,
          "obvPoints": 4,
          "vwapPoints": 0.8,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.JNJ",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 1.8,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 20.66
            }
          },
          "trend": {
            "score": 0.8,
            "details": {
              "qqq": {
                "ma20": 702.2489964000001,
                "ma50": 715.3588015999999,
                "name": "QQQ",
                "close": 683.54999,
                "points": 0.4
              },
              "spy": {
                "ma20": 745.5820062000001,
                "ma50": 744.7240025799999,
                "name": "SPY",
                "close": 741.69,
                "points": 0.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.5673519440484736,
          "atrPoints": 3,
          "cciPoints": 1.6,
          "vixPoints": 1.8,
          "marketTrendPoints": 0.8
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 4,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 2,
              "sentimentScoreRaw": 0.6
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 141061145,
                "url": "https://finnhub.io/api/news?id=857e65287d71e340ebc90b25a158b3ea768e8290cbe58ab973761c737e771160",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson proposed a $5.5b settlement to resolve tens of thousands of ovarian cancer talc lawsuits. The offer aims to address a decade-long legal dispute involving the company’s talcum powder products. The settlement would require approval from a majority of claimants before it can move forward. For investors watching Johnson & Johnson (NYSE:JNJ), this legal development sits alongside a stock that closed at $265.53 and has recently shown strong momentum. The shares are up 3.9% over...",
                "category": "company",
                "datetime": 1785370503,
                "headline": "Johnson & Johnson (JNJ) Seeks $5.5 Billion Talc Lawsuit Settlement"
              },
              {
                "id": 141045214,
                "url": "https://finnhub.io/api/news?id=a5ad14dd721172021d41a7ee6bb937fc646c3fdfabc19b048067b8840759a3c2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson stock has delivered a 77.7% total return over the past five years, yet the latest valuation work suggests the current share price may still sit below an intrinsic value estimate based on a Discounted Cash Flow (DCF) model. At the same time, the broader checks paint a less generous picture, so investors are weighing a strong track record against a low overall value score. Over five years, Johnson & Johnson has returned 77.7%, which keeps the stock firmly in focus for...",
                "category": "company",
                "datetime": 1785258556,
                "headline": "Johnson & Johnson (JNJ) Stock May Be 31% Undervalued As Myeloma Trial Results Impress"
              },
              {
                "id": 141038139,
                "url": "https://finnhub.io/api/news?id=9371cebf2367828f15bdd6a88602fea7fbbb4f663de9acbb55086640ffb65443",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The healthcare company said the agreement covers the remaining ovarian talc litigation in federal multidistrict litigation proceedings and related state court cases.",
                "category": "company",
                "datetime": 1785195376,
                "headline": "JNJ Stock Advances After Hours On $5.5B Proposal To Resolve Talc Litigation"
              },
              {
                "id": 141037166,
                "url": "https://finnhub.io/api/news?id=47fde8cf6cf537b615efc481300dac44cba78e8550ad22fd114ca61fd3aafdec",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) delivered strong fiscal Q2 2026 results, with sales for the quarter growing nearly 7% to $25.31 ⁠billion, above analysts’ average estimate of about $25.05 billion. Adjusted earnings per share reached $2.90, surpassing the expectation of $2.85. The company also raised its full-year guidance and is on track to surpass $100 billion […]",
                "category": "company",
                "datetime": 1785185861,
                "headline": "Johnson & Johnson (JNJ) Raised Its Outlook. Is It the Better Healthcare Stock to Own After Earnings?"
              },
              {
                "id": 141032898,
                "url": "https://finnhub.io/api/news?id=6615fc66077e5d2d0c4d94d8221ea056226840814fa58f92010b88792e506262",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) is one of the health care names that showed up in President Donald Trump’s financial disclosures released earlier this year. Now a top J&J executive is heading the other direction. The Insider Sale EVP of Global Corporate Affairs Vanessa Broadhurst sold 23,054 shares on July 20, a transaction worth close to […]",
                "category": "company",
                "datetime": 1785158883,
                "headline": "President Trump Loves Johnson & Johnson (JNJ), But Insiders Are Selling"
              },
              {
                "id": 141015072,
                "url": "https://finnhub.io/api/news?id=16830e1d8b90f829bbd5e5977c2ddc14c197164f44230010d0e383c3a2102e39",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Healthcare giant Johnson & Johnson (NYSE:JNJ) is one of Jim Cramer’s top healthcare stocks even though the shares have been lackluster. They are up by a modest 27% year-to-date, with most of the gains having come since mid-June. Since June 18th, Johnson & Johnson (NYSE:JNJ)’s stock is up by 15%. As the shares struggled in […]",
                "category": "company",
                "datetime": 1784966368,
                "headline": "Jim Cramer Said To Buy Johnson & Johnson (NYSE:JNJ)’s Shares – Here’s What Happened Next"
              },
              {
                "id": 141012125,
                "url": "https://finnhub.io/api/news?id=df9ddbba648df52ff017922094bd25e71324c6ce3d875d9a4358040044d82db0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson reported highly positive interim Phase 3 results for the TECVAYLI + TALVEY combination in relapsed or refractory multiple myeloma. The trial was unblinded early after the regimen significantly reduced the risk of disease progression and death. The data are expected to inform future regulatory discussions and potential changes to treatment standards in multiple myeloma. For investors tracking Johnson & Johnson (NYSE:JNJ), this oncology update comes with the stock trading...",
                "category": "company",
                "datetime": 1784931178,
                "headline": "Johnson & Johnson (JNJ) Reports Early Phase 3 Win In Multiple Myeloma"
              },
              {
                "id": 141001671,
                "url": "https://finnhub.io/api/news?id=2b3d8469f528d79fb00654c130f687ab423e66a83b114c1d4335fd3db9a5f390",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "J&J’s Ottava clearance knocked Intuitive's shares lower, but recurring revenue and surgeon switching costs suggest the market overreacted.",
                "category": "company",
                "datetime": 1784833972,
                "headline": "J&J Finally Has a Rival to da Vinci. 1 Number in Intuitive Surgical’s Last Quarter Says It Won’t Be Enough to Move the Needle for JNJ Stock."
              }
            ],
            "raw_source": [
              {
                "id": 141071512,
                "url": "https://finnhub.io/api/news?id=b041484e866075d65e42e696876fce75ea4787638210e0360f545c8154e8ff86",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Things are going well for the pharmaceutical giant.",
                "category": "company",
                "datetime": 1785443700,
                "headline": "Johnson & Johnson Just Got FDA Clearance for Its Surgical Robot, Hiked Its Dividend for the 64th Time, and Is Targeting $100 Billion in Revenue. But Here's What Investors Should Be Most Excited About"
              },
              {
                "id": 141071513,
                "url": "https://finnhub.io/api/news?id=81248f8bbc06647644cb887b23d7f303ce176e9168fe7a69f25c0777d1dadd2d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "SAN DIEGO, July 30, 2026--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today reported its second-quarter 2026 financial results and affirmed its key clinical development milestones.",
                "category": "company",
                "datetime": 1785441900,
                "headline": "Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones"
              },
              {
                "id": 141069743,
                "url": "https://finnhub.io/api/news?id=8ec42eaef439eaae7648bdbc5c90e852c9ed0d08fbb47fd2ec676334c0c2e797",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Healthcare stocks declined late Thursday afternoon, with the NYSE Healthcare Index shedding 1.5% and",
                "category": "company",
                "datetime": 1785440768,
                "headline": "Sector Update: Healthcare Stocks Decline Late Afternoon"
              },
              {
                "id": 141069332,
                "url": "https://finnhub.io/api/news?id=bc6262a24c90ed0884245f425e6a54f3ade82a786763155f56cac145e7adfc5d",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Stay updated with the movement of dow jones stocks in today's session. Discover which dow jones stocks are making waves on Thursday.",
                "category": "company",
                "datetime": 1785438605,
                "headline": "Explore the top gainers and losers within the dow jones index in today's session."
              },
              {
                "id": 141068261,
                "url": "https://finnhub.io/api/news?id=6cfd92210b5cfa13302bbc1e31502135dc18dc38c6718516367d30a43337beee",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Healthcare stocks declined Thursday afternoon, with the NYSE Healthcare Index falling 1.7% and the S",
                "category": "company",
                "datetime": 1785432931,
                "headline": "Sector Update: Healthcare Stocks Decline Thursday Afternoon"
              },
              {
                "id": 141069744,
                "url": "https://finnhub.io/api/news?id=d686d3419bdafcaeafad3d97863ed30744904dc6a46393475f4223f32585f7b0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "MRK heads into Q2 earnings with acquisition costs, Keytruda strength and Gardasil challenges likely to shape results. Is the stock still worth holding?",
                "category": "company",
                "datetime": 1785431700,
                "headline": "Should You Buy, Sell or Hold Merck Stock Ahead of Q2 Earnings?"
              },
              {
                "id": 141067645,
                "url": "https://finnhub.io/api/news?id=54c083ca8833104ec3bd833402396dbd380a762e69f889840dbfe2c804963dc9",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Stay updated with the movements of the dow jones index in the middle of the day on Thursday. Discover which stocks are leading as top gainers and losers in today's session.",
                "category": "company",
                "datetime": 1785429605,
                "headline": "Which dow jones stocks are moving on Thursday?"
              },
              {
                "id": 141066698,
                "url": "https://finnhub.io/api/news?id=28e84711ad50dbfa85fde88ffbe2fc182ef5443874fddc18240fc84ca85a8d84",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Bristol Myers Squibb faces declining revenue in its legacy drug portfolio, but new products like Opdivo are offsetting the drop.",
                "category": "company",
                "datetime": 1785420660,
                "headline": "Bristol Myers Stock Rises. Why the Drugmaker Is Lifting Its Earnings Guidance."
              },
              {
                "id": 141064449,
                "url": "https://finnhub.io/api/news?id=809e5299d9985a6bf15571958e544026b0ae39e40f7dfe0e8569e9dbe1160064",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Bristol Myers Squibb faces declining revenue in its legacy drug portfolio, but new products like Opdivo are offsetting the drop.",
                "category": "company",
                "datetime": 1785417480,
                "headline": "Bristol Myers Raises Earnings Guidance as Newer Drugs Drive Big Quarterly Beat"
              },
              {
                "id": 141067646,
                "url": "https://finnhub.io/api/news?id=41281070fe64681d4156832f8e5c670114b284aacd45b50acd6373e4ad03c545",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2233502325/image_2233502325.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "MeiraGTx gene therapy upside: AAV2-hAQP1 for radiation xerostomia targets $3.7B market; Phase 2 data 2Q27. Click for more on MGTX stock.",
                "category": "company",
                "datetime": 1785416251,
                "headline": "Some Potential Merit Within MeiraGTx Holdings"
              },
              {
                "id": 141065435,
                "url": "https://finnhub.io/api/news?id=491fd035b2a2d1ef68d99a79f603351a3fbe73ef12e0cb9db374b4c488d67af6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental Biologics License Application (sBLA) for subcutaneous amivantamab and hyaluronidase-lpuj for adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). If approved, it would provide a new treatment for patients whose disease has progressed following platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor. Priority Review is grante",
                "category": "company",
                "datetime": 1785414600,
                "headline": "Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer"
              },
              {
                "id": 141066699,
                "url": "https://finnhub.io/api/news?id=66eca6562491076bc5babf125861fe41943109985afde42f36c53e9bc95ba5ae",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "US inflation softened last month, with core PCE prices up 0.1% month-on-month in June",
                "category": "company",
                "datetime": 1785412560,
                "headline": "Nasdaq rebounds hard as Microsoft, Apple and chipmakers rally"
              },
              {
                "id": 141068294,
                "url": "https://finnhub.io/api/news?id=3debf7ebe49bfd5017f207c7d47bb095b44390a4aec0db5a16407174bea06243",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The deal with the buzzy Flagship Pioneering-backed startup makes J&J the latest large drugmaker to bet that the technology might be able to treat autoimmune conditions.",
                "category": "company",
                "datetime": 1785412320,
                "headline": "J&J nabs option to buy ‘in vivo’ CAR-T maker Sail for nearly $2.6B"
              },
              {
                "id": 141065262,
                "url": "https://finnhub.io/api/news?id=58a5360ea0dea00271f77d863842593b6696b448732ec0c7851ca1e68bdfc1ad",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1313668225/image_1313668225.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Bristol-Myers Squibb Company hits a 52-week high on Q2 results, EPS guidance raise, and key drugs’ momentum. Read why BMY stock is a buy.",
                "category": "company",
                "datetime": 1785403803,
                "headline": "Bristol-Myers Squibb: Why I'm Still Bullish After Q2"
              },
              {
                "id": 141061145,
                "url": "https://finnhub.io/api/news?id=857e65287d71e340ebc90b25a158b3ea768e8290cbe58ab973761c737e771160",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson proposed a $5.5b settlement to resolve tens of thousands of ovarian cancer talc lawsuits. The offer aims to address a decade-long legal dispute involving the company’s talcum powder products. The settlement would require approval from a majority of claimants before it can move forward. For investors watching Johnson & Johnson (NYSE:JNJ), this legal development sits alongside a stock that closed at $265.53 and has recently shown strong momentum. The shares are up 3.9% over...",
                "category": "company",
                "datetime": 1785370503,
                "headline": "Johnson & Johnson (JNJ) Seeks $5.5 Billion Talc Lawsuit Settlement"
              },
              {
                "id": 141058399,
                "url": "https://finnhub.io/api/news?id=54435742ef35f3fd67a6d343df38f550469a28acbd6223c1a8d77b60b106b94b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "CAMBRIDGE, Mass., July 29, 2026--Sail Biomedicines Announces Strategic Collaboration to Develop New Class of Medicines for In Vivo CAR-T",
                "category": "company",
                "datetime": 1785361500,
                "headline": "Sail Biomedicines Announces Strategic Collaboration to Develop New Class of Medicines for In Vivo CAR-T"
              },
              {
                "id": 141058400,
                "url": "https://finnhub.io/api/news?id=f21fb2df4b7d868f8560135e748cb907da05981f7a2f9d3a5ae849a543973724",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "NEW BRUNSWICK, N.J., July 29, 2026--Johnson & Johnson (NYSE: JNJ) today announced the successful completion of its acquisition of Firefly Bio, Inc., a biotechnology company advancing its proprietary Firelink™ degrader antibody conjugate (DAC) platform, for $1 billion in cash. The Firelink™ DAC platform expands Johnson & Johnson’s oncology portfolio and advances its ambition to develop targeted therapies for some of the most prevalent and difficult-to-treat solid tumors, including KRAS-driven can",
                "category": "company",
                "datetime": 1785361320,
                "headline": "Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation"
              },
              {
                "id": 141058401,
                "url": "https://finnhub.io/api/news?id=16897329aa1cfcef5648424047820095dca78fc7a3daac3ab5d58b68a06b45fe",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "NEW BRUNSWICK, N.J., July 29, 2026--Johnson & Johnson1 (NYSE: JNJ) today announced strategic agreements and collaboration with Sail Biomedicines (Sail), a biotechnology company developing in vivo CAR-T therapies for immune-mediated diseases. Johnson & Johnson will collaborate with Sail to advance its lead immune-mediated disease program and broader platform technology, with incentives to expand the application of Sail's in vivo CAR-T platform across additional therapeutic targets over time. John",
                "category": "company",
                "datetime": 1785360480,
                "headline": "Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset"
              },
              {
                "id": 141058324,
                "url": "https://finnhub.io/api/news?id=15c4df4c5fb54cf1ba96872499789cc422bc41568843a346462416b65eec3566",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "But is that performance sustainable?",
                "category": "company",
                "datetime": 1785360000,
                "headline": "Meet the Stock That's Obliterating Eli Lilly, Johnson & Johnson, and AbbVie Right Now"
              },
              {
                "id": 141059588,
                "url": "https://finnhub.io/api/news?id=67311e2187c8daa5f97909344e3c76b99fbde905a77e989bccdfea2563d55757",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2225310528/image_2225310528.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "NOBL beats SPY YTD in 2026; explore 25 undervalued Dividend Aristocrats with 10%+ projected returns and fresh dividend hikes—see the list now.",
                "category": "company",
                "datetime": 1785354040,
                "headline": "Best Dividend Aristocrats For August 2026"
              },
              {
                "id": 141056950,
                "url": "https://finnhub.io/api/news?id=8450275b1049b512264ab2cc054323bdc6546328d4fe0a9755e4628f1efe126a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Moby summary of Anika Therapeutics, Inc.'s Q2 2026 earnings call",
                "category": "company",
                "datetime": 1785352595,
                "headline": "Anika Therapeutics, Inc. Q2 2026 Earnings Call Summary"
              },
              {
                "id": 141057032,
                "url": "https://finnhub.io/api/news?id=b684972f9145ec821ac0ac385ff638789e56184666fa8e278e4f60b3aacfed9e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "A $3 million portfolio sounds like enough to retire on, but the math gets uncomfortable fast when you need $18,000 a month and a single income strategy quietly destroys the principal it was supposed to protect.",
                "category": "company",
                "datetime": 1785351462,
                "headline": "This $3 Million Portfolio Pays $18,000 a Month From Three Income Buckets"
              },
              {
                "id": 141057017,
                "url": "https://finnhub.io/api/news?id=e2cfd77352aedb0d87503712841214980f53bb4ab61b29927df9b64aee78b575",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The sticker shock on the pharma giant's shares fades once you look at what investors are paying for the earnings expected just two years from now.",
                "category": "company",
                "datetime": 1785348670,
                "headline": "The Real Price of AbbVie Stock Is Cheaper Than You Think"
              },
              {
                "id": 141054929,
                "url": "https://finnhub.io/api/news?id=3d02d113c2ecf29242a7cd994dbb635d3ad841d7d9e5ea68fc7d21924489df69",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Stay updated with the movements of the dow jones index in the middle of the day on Wednesday. Discover which stocks are leading as top gainers and losers in today's session.",
                "category": "company",
                "datetime": 1785343204,
                "headline": "Uncover the latest developments among dow jones stocks in today's session."
              },
              {
                "id": 141055712,
                "url": "https://finnhub.io/api/news?id=51144d4327e88a83da591dfa32e791bae4c1baa83d6c334bfaaca70b95afc0a2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "GSK beats Q2 earnings and revenue estimates, reaffirms 2026 guidance and unveils a new cost-saving plan.",
                "category": "company",
                "datetime": 1785340320,
                "headline": "GSK Beats Q2 Earnings & Revenue Estimates, Announces Cost-Saving Plan"
              },
              {
                "id": 141054047,
                "url": "https://finnhub.io/api/news?id=73d238629d498efdb827745e5672b94a6c855e68df7092faf6295dcac9246948",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Boston Scientific (BSX) lowered its full-year guidance below Wall Street's estimates on Wednesday, c",
                "category": "company",
                "datetime": 1785338822,
                "headline": "Boston Scientific Cuts Outlook Amid Weak Demand for Watchman Heart Device"
              },
              {
                "id": 141054048,
                "url": "https://finnhub.io/api/news?id=ec38063149f2d389816c298503482820d1f1fa803884cc7ed8bbc492e26605e5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Host Kenny Polcari, Robinhood CIO Stephanie Guild, and Payne Capital Management President Ryan Payne discuss why they believe the AI trade is still alive, and how investors can reduce spending risk by looking beyond hyperscalers and semiconductors.",
                "category": "company",
                "datetime": 1785338100,
                "headline": "The new AI trade: Visa, Shopify, and more"
              },
              {
                "id": 141053281,
                "url": "https://finnhub.io/api/news?id=c8e5fec55ce152c1ae6354957dc3bbd151dcbca6a9ba72d322bff0b1a932d8bb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "In the world of robotic surgery, one company is both the undisputed leader and the most expensive name on the shelf, forcing investors to ask if operational brilliance is worth the high price of admission.",
                "category": "company",
                "datetime": 1785332790,
                "headline": "The Best House On The Block Costs The Most: ISRG"
              },
              {
                "id": 141052957,
                "url": "https://finnhub.io/api/news?id=29f92a30df8ade7e656249e4e4a9b585c76fc2f81dc0788a86ee7f8f3e134c8e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Freehand's AI Agents autonomously manage supply-chain spend for Meta, Unilever, Johnson & Johnson, Dunkin', Pfizer and Cardinal Health. Freehand's AI Agents autonomously manage supply-chain spend for Meta, Unilever, Johnson & Johnson, Dunkin', Pfizer and Cardinal Health among others. Freehand builds autonomous AI agents that run supply-chain spend for the world's largest enterprises — taking on procurement, supplier management, invoice and payment operations across complex categories such as log",
                "category": "company",
                "datetime": 1785330000,
                "headline": "Freehand Raises $75M to Scale AI Teams Managing Supply Chain Spend for Fortune 500 Companies"
              },
              {
                "id": 141052126,
                "url": "https://finnhub.io/api/news?id=529dee54f3bc7ee3eb94aa5566f19dc9c0ed643868526e09521e10fde417664a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson's revenue has grown modestly while Eli Lilly's revenue has nearly doubled in two years, narrowing a once-wide gap.",
                "category": "company",
                "datetime": 1785325441,
                "headline": "Johnson & Johnson vs. Eli Lilly: Reliable Stability vs. Rapid Revenue Growth"
              },
              {
                "id": 141051628,
                "url": "https://finnhub.io/api/news?id=2dd0609fece9b7df7d96e884291a99b4db8c8f2618b80ae5cd0c2bffda101783",
                "image": "https://www.chartmill.com/images/uploads/THUMBNAILS_CHARTMILL_1000_528_65_e879a450d1.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "US chip stocks were sold hard on Tuesday in nervous positioning ahead of SK Hynix's print and the overnight results confirmed the fear, with the Korean giant announcing a 2026 capex plan north of $24 billion. Meanwhile, Boeing and Coca-Cola powered the Dow to a 1% gain and Ford lit up after-hours with an earnings beat, all a day before the Fed decides.",
                "category": "company",
                "datetime": 1785316364,
                "headline": "Chips Sell First, Ask Questions Later - And SK Hynix Just Handed Them the Answer"
              },
              {
                "id": 141052272,
                "url": "https://finnhub.io/api/news?id=75b6db24b6cf7e3f5c0f42f150ad606e3cae5edba16b5a5256b43abe742b532e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Retiring at 60 with a five-figure monthly paycheck sounds like it requires decades of maxing every tax-advantaged account you own, but a taxable brokerage and the right yield strategy can tell a very different story for a 44-year-old with 16 years on the clock.",
                "category": "company",
                "datetime": 1785284929,
                "headline": "How a 44-Year-Old Could Build a $9,000 Monthly Paycheck by 60 Without Maxing a 401(k)"
              },
              {
                "id": 141048289,
                "url": "https://finnhub.io/api/news?id=b598a6df1535b43ec4837ef88437ce4d0de5492978b318a73e863f427387a2bd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Abbott Laboratories, Taiwan Semiconductor, and Johnson & Johnson have all delivered strong earnings releases in the Q2 cycle, with each breaking records while also lifting their outlooks.",
                "category": "company",
                "datetime": 1785274080,
                "headline": "These 3 Companies Reported Record Results and Raised Guidance"
              },
              {
                "id": 141047335,
                "url": "https://finnhub.io/api/news?id=9d58799aab8aaf0469fd9b5b65014ae6bb3a53c7d399f380b298b88f029b743d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Generating $7,000 a month in retirement sounds like a math problem, but for Medicare-eligible investors it's also a tax trap where chasing a higher yield can quietly trigger surcharges that claw back the gains.",
                "category": "company",
                "datetime": 1785274004,
                "headline": "A $1.2 Million Portfolio That Pays $7,000 a Month and Stays Below the IRMAA Surcharge Line"
              },
              {
                "id": 141047303,
                "url": "https://finnhub.io/api/news?id=556426890a3fac26e5447912eb362cc02010df281b0dcb32f90c4409a7a36c9e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson stock's oncology engine and its steady guidance raises were on the record quarters before the price moved.",
                "category": "company",
                "datetime": 1785271965,
                "headline": "What Johnson & Johnson Stock Told You Before It Surged"
              },
              {
                "id": 141047304,
                "url": "https://finnhub.io/api/news?id=964cb7fb943f3d27b92bfa4cd03543b70ad5d97017a3e0c9b5c997db08924eeb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "One of the market's strongest health care performers barely moves with the index you already own, and that gap is the whole point.",
                "category": "company",
                "datetime": 1785271282,
                "headline": "Does Eli Lilly Stock Actually Diversify Your Portfolio?"
              },
              {
                "id": 141047338,
                "url": "https://finnhub.io/api/news?id=5fe9facac7edcd294c3dd5bddcba8b04d1e3f6701d682844fda336bb13595758",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Haemonetics Corporation (NYSE: HAE) a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, announced today that Martin Madaus has been elected to the Company's Board of Directors, effective July 24, 2026.",
                "category": "company",
                "datetime": 1785269700,
                "headline": "Martin Madaus Elected to Haemonetics Board of Directors"
              },
              {
                "id": 141045089,
                "url": "https://finnhub.io/api/news?id=5bbe7a30993af553cfe0eafa8b968ab5d0af20fdf11789bbd7af2ca91da127f2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Coca-Cola and Boeing are surging together for the first time in years as investors abandon AI darlings, and the catalyst behind each stock tells a very different story about where the market is heading.",
                "category": "company",
                "datetime": 1785260594,
                "headline": "Boeing Jumps 6%, Coca-Cola Gains 4% in a Dow Double-Shot as Money Rotates Out of AI"
              },
              {
                "id": 141045214,
                "url": "https://finnhub.io/api/news?id=a5ad14dd721172021d41a7ee6bb937fc646c3fdfabc19b048067b8840759a3c2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson stock has delivered a 77.7% total return over the past five years, yet the latest valuation work suggests the current share price may still sit below an intrinsic value estimate based on a Discounted Cash Flow (DCF) model. At the same time, the broader checks paint a less generous picture, so investors are weighing a strong track record against a low overall value score. Over five years, Johnson & Johnson has returned 77.7%, which keeps the stock firmly in focus for...",
                "category": "company",
                "datetime": 1785258556,
                "headline": "Johnson & Johnson (JNJ) Stock May Be 31% Undervalued As Myeloma Trial Results Impress"
              },
              {
                "id": 141046312,
                "url": "https://finnhub.io/api/news?id=c28aa1c884cffdf993088c8b520ca68dbb6e087a14c00a11fcf3e0a0dd7be102",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "AbbVie heads into Q2 earnings with Skyrizi and Rinvoq driving growth as investors weigh Humira declines and the company's long-term outlook.",
                "category": "company",
                "datetime": 1785258360,
                "headline": "Should You Buy, Hold or Sell ABBV Stock Ahead of Q2 Earnings?"
              },
              {
                "id": 141046313,
                "url": "https://finnhub.io/api/news?id=7e1fd587a8d26e853aee078e591c648a185395830c97a0f247456c2c375a4972",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson says it will pay an estimated $5.5 billion to settle about 76,000 lawsuits alleging its baby powder and talc caused ovarian cancer.",
                "category": "company",
                "datetime": 1785255463,
                "headline": "Johnson & Johnson agrees to pay $5.5B to settle talc lawsuits"
              },
              {
                "id": 141044381,
                "url": "https://finnhub.io/api/news?id=d30853e65c00378415d30d59a5967ff2f900939f6907ae3ee97252353d3efa08",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "DGRO markets itself as a sleepy dividend fund, but its rulebook quietly funnels money toward mega-cap tech, and the compounding math behind that combination may rewrite which ETF actually wins over the next decade.",
                "category": "company",
                "datetime": 1785254149,
                "headline": "Prediction: This ‘Boring’ Dividend ETF Secretly Rides the AI Trade and Out-Earns Your High-Yield Fund by 2036"
              },
              {
                "id": 141043603,
                "url": "https://finnhub.io/api/news?id=70471c9d07086e277f0946f78512534c01b8d5bd3a0a975be31830765e9e4831",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) has reached an agreement to resolve tens of thousands of lawsuits in the US alleging that its talc-based products, including its baby powder, caused ovarian cancer, with the company committing up to $5.5 billion to settle the remaining claims. The proposed...",
                "category": "company",
                "datetime": 1785252360,
                "headline": "Johnson & Johnson proposes $5.5B settlement to resolve remaining talc litigation"
              },
              {
                "id": 141043604,
                "url": "https://finnhub.io/api/news?id=b1d8219b0da7dca90728d00b0fd6a005cc34e189fc6714405c30106eefeee448",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson has set aside $5.5 billion to resolve tens of thousands of US lawsuits alleging that its talcum powder-based products caused ovarian cancer.",
                "category": "company",
                "datetime": 1785248519,
                "headline": "Johnson & Johnson offers up to $5.5 billion to settle baby powder cancer lawsuits"
              },
              {
                "id": 141043605,
                "url": "https://finnhub.io/api/news?id=a4e736a3943de92c3e20fe48a9e14561506db203f58dc45385bcab5c4e89fedc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Biotech earnings take center stage as Viking, Biogen, Bristol Myers, Regeneron and AbbVie prepare to report Q2 2026 results.",
                "category": "company",
                "datetime": 1785247620,
                "headline": "Can These 5 Biotech Stocks Beat Wall Street's Q2 Estimates?"
              },
              {
                "id": 141042379,
                "url": "https://finnhub.io/api/news?id=cf402ac4137131c67fe9ce5ec6dee69ba871bfbe404b1e3a236feca70be98daf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "ASML, Sandisk, Micron, and other AI stocks struggle as investors fret over rising costs and competition from China.",
                "category": "company",
                "datetime": 1785242280,
                "headline": "Corning, ASML, PayPal, UPS, Boeing, and More Stocks That Explain Today’s Market"
              },
              {
                "id": 141042506,
                "url": "https://finnhub.io/api/news?id=f6d3970dab46747734b14e6aa7ea3c6dfd4f0ffd50d3fc471c540f715b0dbee4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The deal covers about 76,000 ovarian cancer claims and requires acceptance by at least 95% of claimants to take effect",
                "category": "company",
                "datetime": 1785240826,
                "headline": "Johnson & Johnson settling talc baby powder lawsuits for $5.5 billion"
              },
              {
                "id": 141042507,
                "url": "https://finnhub.io/api/news?id=7ecd511924e1b4620a20d45fc48c19e71a9cd1c7e713d1a6eca64b2471ef0521",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson has agreed to pay $5.5 billion to tie up remaining lawsuits that claim its talc products caused ovarian cancer.  The drugmaker, which has been fighting talc-related lawsuits for more than a decade, said that the settlement is conditioned on at least 95% of remaining claimants participating.  A U.S. bankruptcy court judge denied a $9 billion settlement proposed by company subsidiary Red River Talc last year that would have been one of the biggest mass tort settlements in history.",
                "category": "company",
                "datetime": 1785240759,
                "headline": "Johnson & Johnson proposes $5.5 billion talc settlement to end marathon legal fight"
              },
              {
                "id": 141041614,
                "url": "https://finnhub.io/api/news?id=09fe5cf46a950fb057b6c6441ee11f6db9f662dfd5574829b681f8371ac3369f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Micron, Nvidia, and other AI stocks struggle as investors fret about rising costs and competition from China.",
                "category": "company",
                "datetime": 1785236100,
                "headline": "ASML, Sandisk, Apple, and More Stocks That Explain Today’s Market"
              },
              {
                "id": 141041718,
                "url": "https://finnhub.io/api/news?id=fb2de916f242716eebb512ac41558c891e2eb99487a2eed0cf8d56eb3b62d179",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (J&J) has agreed to pay an estimated $5.5bn (£4.1bn) to resolve tens of thousands of claims that its baby powder caused ovarian cancer.",
                "category": "company",
                "datetime": 1785233862,
                "headline": "Johnson & Johnson offers £4.1bn to settle talcum powder cancer claims"
              },
              {
                "id": 141041719,
                "url": "https://finnhub.io/api/news?id=f7794fa107ad1c96a9638a5920e0628b2dc28131e14ba027a9df3dfa53c657be",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "STORY: :: New York / July 27, 2026:: Dietrich Knauth, Legal Reporter\"After years of litigation, about 70,000 court cases, and three bankruptcies, Johnson& Johnson has agreed to a $5.5 billion talc settlement. Why are they settling now? :: Why did J&J settle after more than a decade of talc litigation?\"So tens of thousands of women have accused Johnson& Johnson of causing their ovarian cancer. They've alleged that talc-based products, including baby powder, have been contaminated with asbestos and caused them to develop cancer after using these products for a long period of time. Johnson& Johnson has denied that, but these cases have continued to go to trial.\"\"And after a couple of attempts to settle these cases through bankruptcy courts, Johnson& Johnson has now reached a deal where they think they can end all of these cases for an overall payment that is about $5.5 billion, although that number could rise depending on how many people participate in the settlement.\"\"One of the plaintiff's lawyers told me today that he thinks it's closer to $7 billion. That's not something we're going to know for some time.\":: Could J&J still face new talc lawsuits in the future?:: Johnson & Johnson\"It does not fully close the door on all future talc litigations. Somebody could develop cancer in the future, decide that they want to file a lawsuit against Johnson& Johnson, because they think that company's product caused their cancer. The reason for that is that there's something called a latency period, which is essentially the delay between when you experience the factors that caused your cancer and when that cancer actually shows up.\"\"But, you know, this deal basically gets rid of all of the existing cases. That's the idea.\"J&J reached the settlement after a series of wins in court, including victories in individual trials, successful efforts to disqualify plaintiffs' lawyers from the litigation, and court rulings against experts that plaintiffs had used to prove their cases in court. J&J won a significant court victory in the long-running legal battle last week, when a federal judge cast doubt on individual plaintiffs' ability to prove that talc specifically caused their ovarian cancer.J&J has long denied that its talc products caused cancer, saying that talc was safe and did not contain asbestos. The company stopped selling talc-based baby powder in the U.S. in 2020, switching to a cornstarch product.Before the bankruptcy attempts, J&J had a mixed record in talc trials, with a multibillion verdict in favor of 22 women who said baby powder caused their ovarian cancer. The company won some trials outright and had other verdicts reduced on appeal.Unlike the proposed bankruptcy settlements, Monday's agreement applies only to existing claims and does not address future lawsuits.",
                "category": "company",
                "datetime": 1785233798,
                "headline": "Johnson & Johnson reaches $5.5 billion baby powder settlement"
              },
              {
                "id": 141048146,
                "url": "https://finnhub.io/api/news?id=6bb82aad805c6a173e46be241afba15536fff4a89d414816e0eb8f701add24ee",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/28/Johnson--Johnson-Inc--JNJ.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Johnson & Johnson reached a $5.5 billion agreement to resolve remaining federal and state talc litigation over ovarian cancer claims.",
                "category": "company",
                "datetime": 1785233415,
                "headline": "Johnson & Johnson Puts 15-Year Meritless Talc Litigation To Rest"
              },
              {
                "id": 141044756,
                "url": "https://finnhub.io/api/news?id=d14fc42e1224031db556d307ad7a1a9884340080d91c78d74e3c2834c83a14de",
                "image": "https://image.cnbcfm.com/api/v1/image/108341064-17852451311785245128-47436861526-1080pnbcnews.jpg?v=1785245130&w=1920&h=1080",
                "source": "CNBC",
                "related": "JNJ",
                "summary": "CNBC’s Jim Cramer delivers his daily Mad Dash.",
                "category": "company",
                "datetime": 1785231260,
                "headline": "Cramer’s Mad Dash: Johnson & Johnson"
              },
              {
                "id": 141041141,
                "url": "https://finnhub.io/api/news?id=7efcce9b986f0bcbe02c9f4c76eed19a893d828ee96ff7b766a056dca8aef345",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (JNJ) has agreed to commit up to $5.5 billion to settle about 76,000 lawsuits that",
                "category": "company",
                "datetime": 1785230308,
                "headline": "Johnson & Johnson Proposes to Pay Up to $5.5 Billion to Resolve Remaining Ovarian Cancer Claims"
              },
              {
                "id": 141041720,
                "url": "https://finnhub.io/api/news?id=4340760a7e45a140e669280168a7ec7a122e4f7bb43f8b9c7ee0b3f947ca31d1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "HRMY, ACAD, BIIB, INSM and AGIO are set to report Q2 results, with positive Earnings ESPs suggesting potential earnings surprises.",
                "category": "company",
                "datetime": 1785229080,
                "headline": "The Zacks Analyst Blog Highlights Harmony Biosciences, Acadia Pharmaceuticals, Biogen, Insmed and Agios Pharmaceuticals"
              },
              {
                "id": 141043182,
                "url": "https://finnhub.io/api/news?id=ac104a67ca1b9e27d98ed0961b8b951563c2a4c8ef00020a7f7f4037246307d8",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/28/Close-Up-Of-Wall-Street-Sign-With-Iconic.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "U.S. stock futures were mixed on Tuesday, as the Dow Jones and S&P 500 indices gained but Nasdaq 100 slipped, following Monday's mixed close.",
                "category": "company",
                "datetime": 1785227916,
                "headline": "Stock Market Today: Dow Jones Futures Gain as Coca-Cola Jumps After Q2 Beat, S&P 500, Nasdaq 100 Decline—Boeing, Johnson & Johnson in Focus (UPDATED)"
              },
              {
                "id": 141044757,
                "url": "https://finnhub.io/api/news?id=83ec0a734e4684dd86073c4106e59f28adc43ca5a809c32d543ada0095e7e245",
                "image": "https://image.cnbcfm.com/api/v1/image/108214025-1760961000162-gettyimages-2241840811-20090101251020-99-382295.jpeg?v=1760961104&w=1920&h=1080",
                "source": "CNBC",
                "related": "JNJ",
                "summary": "These are the stocks posting the largest moves in early trading.",
                "category": "company",
                "datetime": 1785223795,
                "headline": "Stocks making the biggest moves premarket: Coca-Cola, Sherwin-Williams, Johnson & Johnson & more"
              },
              {
                "id": 141040688,
                "url": "https://finnhub.io/api/news?id=f7c8f9fd65cd52e3f453d37e8652191d4ffe3107f93a810ee1d085f8c845d689",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson has offered $5.5 billion to settle tens of thousands of lawsuits claiming its baby powder and other talcum powder products caused ovarian cancer, the company says.",
                "category": "company",
                "datetime": 1785220380,
                "headline": "Johnson & Johnson offers $5.5 billion to settle talc lawsuits"
              },
              {
                "id": 141044758,
                "url": "https://finnhub.io/api/news?id=5c9e5cd11bb849854a0b3625768e424bc5d044d5e7ac037e19d31a2d57d31460",
                "image": "https://image.cnbcfm.com/api/v1/image/108340946-3ED1-REQ-072826-NewsPRE1.jpg?v=1785233655&w=1920&h=1080",
                "source": "CNBC",
                "related": "JNJ",
                "summary": "CNBC brings you fast, accurate, and actionable business news and market updates.",
                "category": "company",
                "datetime": 1785219399,
                "headline": "The Pre-Market Rundown: July 28, 2026"
              },
              {
                "id": 141040296,
                "url": "https://finnhub.io/api/news?id=2902aa5d42f4824b93848fd840600a041410c9aba7f7af5c6db6f7e42759e4df",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (J&J) has offered to pay $5.5bn (£4.13bn) to resolve tens of thousands of lawsuits in the US alleging its talcum powder caused ovarian cancer.  The company said the settlement covers around 76,000 claims, having already settled most cases alleging its talc contained asbestos and caused mesothelioma.  J&J's vice president of litigation, Erik Haas, said the move was motivated by a desire to get closure – describing the claims themselves as \"meritless\".",
                "category": "company",
                "datetime": 1785213360,
                "headline": "J&J offers $5.5bn to settle baby powder lawsuits"
              },
              {
                "id": 141048148,
                "url": "https://finnhub.io/api/news?id=f9902f3084ba88575fd64b85ef874c7d0cba5a26639fd8eb580cde4c7c3f1469",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Follows Favorable Multi-District Litigation Court Causation Ruling and the Company’s Successful Strategy to Defend Each CaseEfficient Conclusion to the Talc Litigation that Eliminates Expense Associated with Litigating",
                "category": "company",
                "datetime": 1785210063,
                "headline": "Reported Earlier, Johnson & Johnson Proposes $5.5B Resolution Of Roughly 76,000 Ovarian Talc Claims, With First Payment Of Up To $3B In 2027, Conditioned On 95% Plaintiff Participation"
              },
              {
                "id": 141038944,
                "url": "https://finnhub.io/api/news?id=bc0964d4fcd04c2db4bf47a142b98d6e200881d9fef4cf6139866213b06817b7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The yield you chase in retirement does not just shape your income, it determines whether your portfolio outlasts you or quietly devours itself. Two investors with the same $600,000 can end up hundreds of thousands of dollars apart depending on one number.",
                "category": "company",
                "datetime": 1785198324,
                "headline": "Why Chasing a 9% Yield Could Cost You $200,000 in Retirement Income"
              },
              {
                "id": 141038139,
                "url": "https://finnhub.io/api/news?id=9371cebf2367828f15bdd6a88602fea7fbbb4f663de9acbb55086640ffb65443",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The healthcare company said the agreement covers the remaining ovarian talc litigation in federal multidistrict litigation proceedings and related state court cases.",
                "category": "company",
                "datetime": 1785195376,
                "headline": "JNJ Stock Advances After Hours On $5.5B Proposal To Resolve Talc Litigation"
              },
              {
                "id": 141038140,
                "url": "https://finnhub.io/api/news?id=4389e6bde661713a20cd1e5e49cee3820ef92d4f5a49924c04413b06e7d7fb27",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "NEW BRUNSWICK, N.J., July 27, 2026--Johnson & Johnson (NYSE: JNJ) (the \"Company\") today announced that it has reached an agreement for a comprehensive resolution of the remaining talc litigation with the plaintiff firms leading the federal Multi-District Litigation (MDL) and related state court proceedings, conditioned on, among other things, the express participation of at least 95% of the remaining claims. The proposed resolution follows a favorable ruling by the MDL court, and acknowledgment",
                "category": "company",
                "datetime": 1785191460,
                "headline": "Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation"
              },
              {
                "id": 141037166,
                "url": "https://finnhub.io/api/news?id=47fde8cf6cf537b615efc481300dac44cba78e8550ad22fd114ca61fd3aafdec",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) delivered strong fiscal Q2 2026 results, with sales for the quarter growing nearly 7% to $25.31 ⁠billion, above analysts’ average estimate of about $25.05 billion. Adjusted earnings per share reached $2.90, surpassing the expectation of $2.85. The company also raised its full-year guidance and is on track to surpass $100 billion […]",
                "category": "company",
                "datetime": 1785185861,
                "headline": "Johnson & Johnson (JNJ) Raised Its Outlook. Is It the Better Healthcare Stock to Own After Earnings?"
              },
              {
                "id": 141037167,
                "url": "https://finnhub.io/api/news?id=77af2bd8392e02f9187a98e53b9e7e0817d0974616c0cf27aaa3425dad8caed4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Dr. Rooney, former immunology leader at Johnson & Johnson, will lead clinical development strategy across Kymera’s industry-leading oral immunology portfolio Jared Gollob, MD, will retire from his role after eight years of leadership at the Company WATERTOWN, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the ap",
                "category": "company",
                "datetime": 1785182460,
                "headline": "Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer"
              },
              {
                "id": 141037135,
                "url": "https://finnhub.io/api/news?id=f039384443066be35bc6ced345a619fa1e6911431bbd02d74d2a8573ae541097",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The drugmaker's rapid stock gains have led to a premium valuation, forcing investors to question its capacity for future growth.",
                "category": "company",
                "datetime": 1785182092,
                "headline": "The Engine Behind ABBV Stock Has Real Parts"
              },
              {
                "id": 141037136,
                "url": "https://finnhub.io/api/news?id=1962630925adf572941ee3d09545871641e85445ce685d06cecba1d3bddbddb1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "UNH's post-earnings pullback follows a 52-week high, as stronger guidance offsets Medicaid pressures and spotlights healthcare ETFs with sizable exposure.",
                "category": "company",
                "datetime": 1785180480,
                "headline": "UnitedHealth Pulls Back Post 52-Week High: Healthcare ETFs to Watch"
              },
              {
                "id": 141036037,
                "url": "https://finnhub.io/api/news?id=2cc61cdbabe57465c6369f88d1cd57b760ec36da2bc51946d6d2f08f0584f756",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Here is a way to get paid a significant income stream today from Eli Lilly stock, which you keep no matter what, while setting a price far below current levels where you would be willing to buy.",
                "category": "company",
                "datetime": 1785177225,
                "headline": "Collect 9.8% On LLY Stock Now, Own It 30% Cheaper If It Dips"
              },
              {
                "id": 141035128,
                "url": "https://finnhub.io/api/news?id=b58d464b27d7f23f9a829bbedeecdcfeaa6027ba0087c79c62c1a13671ff8765",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Harmony Biosciences, Acadia, Biogen, Insmed and Agios show positive Earnings ESPs ahead of Q2 results, setting up closely watched earnings reports.",
                "category": "company",
                "datetime": 1785170160,
                "headline": "Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?"
              },
              {
                "id": 141035129,
                "url": "https://finnhub.io/api/news?id=c92ef4a473af545abf93085c0feb833d345113b7ee6e12a65912c65c41f0d0ff",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "J&J's MedTech growth slowed down in Q2 as Cardiovascular lagged, but new product launches and stronger Vision, Surgery and Orthopedics may lift H2 sales.",
                "category": "company",
                "datetime": 1785167220,
                "headline": "J&J's MedTech Performance Slows in Q2: Will Sales Improve in H2?"
              },
              {
                "id": 141033665,
                "url": "https://finnhub.io/api/news?id=226e97769226d352193ee468abc933e80443ec0634412daea81166b5b2cba6ca",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "A 2.8% Social Security raise barely covers a trip to the grocery store, so retirees are quietly rebuilding their paychecks around five dividend stocks with track records stretching back through every recession of the past two decades.",
                "category": "company",
                "datetime": 1785166830,
                "headline": "Forget Social Security: 5 Sleep-at-Night Dividend Stocks Retirees Are Using to Replace a Paycheck"
              },
              {
                "id": 141032898,
                "url": "https://finnhub.io/api/news?id=6615fc66077e5d2d0c4d94d8221ea056226840814fa58f92010b88792e506262",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) is one of the health care names that showed up in President Donald Trump’s financial disclosures released earlier this year. Now a top J&J executive is heading the other direction. The Insider Sale EVP of Global Corporate Affairs Vanessa Broadhurst sold 23,054 shares on July 20, a transaction worth close to […]",
                "category": "company",
                "datetime": 1785158883,
                "headline": "President Trump Loves Johnson & Johnson (JNJ), But Insiders Are Selling"
              },
              {
                "id": 141032152,
                "url": "https://finnhub.io/api/news?id=c9cdc9b27f60fb3ee8e170927c5226a3a2b0d43646e685a4c0755d0565d70fa0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "GM, ABT and JNJ stand out this earnings season after raising guidance, boosting outlooks and reinforcing momentum with stronger-than-expected quarterly results.",
                "category": "company",
                "datetime": 1785145260,
                "headline": "Zacks Investment Ideas feature highlights: General Motors, Abbott Laboratories and Johnson & Johnson"
              },
              {
                "id": 141031076,
                "url": "https://finnhub.io/api/news?id=62173fbda2301693a92f3d5da56390b4ea3db8e08c290385b475eabf6e1d5a7b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The company that used to reassure you with its sheer breadth now leads with a push to dominate oncology, and a holder who bought a diversified compounder should notice the bet has changed shape.",
                "category": "company",
                "datetime": 1785135053,
                "headline": "Johnson & Johnson Now Leads Its Pitch With An Oncology Bet"
              },
              {
                "id": 141030812,
                "url": "https://finnhub.io/api/news?id=4b6e6d93296faed73bb2ef8ae9464545cf430aa9aee7768bdfe0f63f83fd0474",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2232218380/image_2232218380.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Veradermics is well-funded through the expected FDA submission in early 2027 and potential commercial launch in 2028. See why MANE stock is a Hold.",
                "category": "company",
                "datetime": 1785119424,
                "headline": "Veradermics: Wait For The Post-Lockup, But Buy Before The Roll-Up"
              },
              {
                "id": 141026817,
                "url": "https://finnhub.io/api/news?id=e83e5a8e0a8629b76fe9443999860bb064d143c549fc24404d45d48ca34ca42e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Stopping work at 62 while waiting for a bigger Social Security check sounds clean on paper, but the math gets complicated fast when a portfolio has to carry the entire household for years. Here is how much capital different yield strategies actually require, and which tradeoffs could quietly wreck the plan.",
                "category": "company",
                "datetime": 1785095554,
                "headline": "A $550,000 Portfolio That Quietly Pays a 62-Year-Old $3,400 a Month Until Social Security Kicks In"
              },
              {
                "id": 141028474,
                "url": "https://finnhub.io/api/news?id=9a2687b22714d8cedc636831b2bc62592056cb84c4baeb1b206ee7ea9c167dc4",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2209914068/image_2209914068.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Dividend Kings beat SPY in June–July, reclaiming a YTD lead.",
                "category": "company",
                "datetime": 1785093714,
                "headline": "Best Dividend Kings: July 2026"
              },
              {
                "id": 141025855,
                "url": "https://finnhub.io/api/news?id=b4c5c273ea2ff189dfa396040dbf45b5f6cab27bbecbd89f4a3b4abb399534a3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Generating $48,000 a year in dividends sounds like a retirement fantasy until you see how the math actually splits across three very different yield strategies, each demanding a radically different amount of starting capital and carrying its own hidden cost.",
                "category": "company",
                "datetime": 1785084681,
                "headline": "How to Build $4,000 a Month in Dividend Income Without Selling a Single Share"
              },
              {
                "id": 141023888,
                "url": "https://finnhub.io/api/news?id=0e7c8b9ce48492e0870a97c7e8778cdbf2f0ff180e2b5db500c5b8c844969d64",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Both have very promising futures.",
                "category": "company",
                "datetime": 1785060420,
                "headline": "Better Dividend King to Buy Right Now: AbbVie or Johnson & Johnson?"
              },
              {
                "id": 141023596,
                "url": "https://finnhub.io/api/news?id=aa93f6b650dcda9f8826f3f7390c5a02e2548ec74e81335b1ebe7541cf3f7d9d",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2187254257/image_2187254257.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Track this week’s market catalysts: Big Tech earnings, Fed rate decision, and core PCE inflation data—plus IPOs and key reports.",
                "category": "company",
                "datetime": 1785048021,
                "headline": "Wall Street Week Ahead"
              },
              {
                "id": 141021018,
                "url": "https://finnhub.io/api/news?id=3a21c791543218a3dcf776fa77cd33387f0d0b3f1fefebf9bce8f21d87cc57f5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "A $2 million retirement portfolio can generate wildly different income streams depending on where you put it, and choosing the wrong tier does not just leave money on the table. It can quietly eat your principal alive while you think you are getting rich.",
                "category": "company",
                "datetime": 1785023295,
                "headline": "The $2 Million Retirement Mistake: Confusing Yield With Income You Can Actually Spend"
              },
              {
                "id": 141020270,
                "url": "https://finnhub.io/api/news?id=7f9ee9e9891472b3ca8091ba21bc032ee3ef7180d7a8dcfe3d6ab7139cd24513",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Waiting until 70 to claim Social Security sounds simple until you calculate the eight years of income you need to survive without it. The dividend tier you choose to fill that gap could determine whether you arrive at 75 richer or quietly broke.",
                "category": "company",
                "datetime": 1785019617,
                "headline": "Claiming Social Security at 62 vs. Building a Dividend Bridge: Which Leaves You Richer at 75?"
              },
              {
                "id": 141016864,
                "url": "https://finnhub.io/api/news?id=02a7054929fccd13b94135fcc42ef9eaf195056dd9ae3898a266d92a88bdf526",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Management's plain health care label has slipped out of the lead, and the business now on a separation clock is the one that finally started working.",
                "category": "company",
                "datetime": 1784989802,
                "headline": "Johnson & Johnson Is Becoming A Narrower Company Than You Bought"
              },
              {
                "id": 141015956,
                "url": "https://finnhub.io/api/news?id=30c853daab5af443ab8a0c8862a8b56eabb48569926bf56471b440d71080bbab",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/attachment/image/1d2aed9fc253168620c030b0153c6b23.png?io=w640",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Wall Street Breakfast recap: stocks slide on oil surge, tech earnings, tariffs and Middle East tensions.",
                "category": "company",
                "datetime": 1784970358,
                "headline": "What Moved Markets This Week"
              },
              {
                "id": 141015072,
                "url": "https://finnhub.io/api/news?id=16830e1d8b90f829bbd5e5977c2ddc14c197164f44230010d0e383c3a2102e39",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Healthcare giant Johnson & Johnson (NYSE:JNJ) is one of Jim Cramer’s top healthcare stocks even though the shares have been lackluster. They are up by a modest 27% year-to-date, with most of the gains having come since mid-June. Since June 18th, Johnson & Johnson (NYSE:JNJ)’s stock is up by 15%. As the shares struggled in […]",
                "category": "company",
                "datetime": 1784966368,
                "headline": "Jim Cramer Said To Buy Johnson & Johnson (NYSE:JNJ)’s Shares – Here’s What Happened Next"
              },
              {
                "id": 141012890,
                "url": "https://finnhub.io/api/news?id=5c10bc0162533a4bf0bf35e19474439a697677179f95faaee57891b759074e87",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Stripe is reportedly circling PayPal in a deal that could end a frustrating run for the fintech giant, but is it a good enough deal?",
                "category": "company",
                "datetime": 1784943415,
                "headline": "Does PayPal Have a Buyer?"
              },
              {
                "id": 141012101,
                "url": "https://finnhub.io/api/news?id=4e1e23cf08396f986f5b9a6bb8cb7b76eaa05c1892763d61ed11183134d2e9c9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "STORY: U.S. stocks ended mixed on Friday, with the Dow gaining just under half a percent, the S&P 500 virtually flat and the tech-heavy Nasdaq sliding nearly two-thirds of a percent.The S&P 500 technology index underperformed the broader market as chip stocks fell, with Intel dropping nearly 8% despite forecasting quarterly profit and revenue above Wall Street estimates.Enthusiasm for the AI trade weakened after Alphabet's announcement earlier this week of a plan to hike capital spending even as it burns cash.Richard Reyle, chief investment officer at Questar Capital Partners, said that as a result investors are rotating into what he called \"safer parts of the market.\"\"Pharmaceuticals have been flying, and that's been, I think, where we see the rotation of the market right now. [FLASH] You look at the iShares, pharmaceutical fund, it's big components that are J&J and Eli Lilly, they're at all-time highs. And they're still relatively not super expensive stocks. So I think that's a place that can be bought and held. And of course, energy. Exxon's going to announce earnings next week. I bet they're going to be a blockbuster and they're going to continue to be because they make money at $60 a barrel. At $100 a barrel, forget about it. They do very well.\"The S&P 500 real estate sector also outperformed during the session. Its leading gainer was Digital Realty Trust, which rallied 11% after it raised its full-year forecast for funds from operations.Among other gainers, shares of SLB climbed 11% after the oilfield services firm beat expectations for second-quarter profit.Investors now turn their attention to quarterly results next week from Magnificent 7 megacaps Microsoft, Amazon, Meta and Apple.",
                "category": "company",
                "datetime": 1784931586,
                "headline": "Nasdaq lags on angst over AI spending ahead of earnings reports"
              },
              {
                "id": 141012125,
                "url": "https://finnhub.io/api/news?id=df9ddbba648df52ff017922094bd25e71324c6ce3d875d9a4358040044d82db0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson reported highly positive interim Phase 3 results for the TECVAYLI + TALVEY combination in relapsed or refractory multiple myeloma. The trial was unblinded early after the regimen significantly reduced the risk of disease progression and death. The data are expected to inform future regulatory discussions and potential changes to treatment standards in multiple myeloma. For investors tracking Johnson & Johnson (NYSE:JNJ), this oncology update comes with the stock trading...",
                "category": "company",
                "datetime": 1784931178,
                "headline": "Johnson & Johnson (JNJ) Reports Early Phase 3 Win In Multiple Myeloma"
              },
              {
                "id": 141012126,
                "url": "https://finnhub.io/api/news?id=a6b3d3b8c03098c58b1346b2c6d34207a883c82b0665d95e74987a6c7995738c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Replacing a Social Security check with dividend income sounds straightforward until you realize the yield you chase changes the capital required by more than a million dollars. The tier you pick carries tradeoffs most income investors only discover after the fact.",
                "category": "company",
                "datetime": 1784931123,
                "headline": "How Much Do You Need Invested to Match the Maximum Social Security Benefit With Dividends?"
              },
              {
                "id": 141012380,
                "url": "https://finnhub.io/api/news?id=1049f08222cb659a27f732cbe315d0815331fce9aae8adcb12d874d1f0f61c7c",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2262233592/image_2262233592.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Regeneron Pharmaceuticals, Inc. buy case: Dupixent & Libtayo fuel growth despite volatility & Eylea biosimilar risks; margins to recover. Click for an REGN update.",
                "category": "company",
                "datetime": 1784924522,
                "headline": "Regeneron: I'm Not Concerned About The Declining ROIC And Operating Margins"
              },
              {
                "id": 141008873,
                "url": "https://finnhub.io/api/news?id=0a485f1fa08b431da2d3ffb0109a55c9e9c924b2f7213f2766d5efe23d30f2e8",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Wondering what's happening in today's session for the dow jones index? Stay informed with the top movers within the dow jones index on Friday.",
                "category": "company",
                "datetime": 1784920204,
                "headline": "Which dow jones stocks are moving on Friday?"
              },
              {
                "id": 141007741,
                "url": "https://finnhub.io/api/news?id=d7584817bec7c3ef4b0c8862f86610832afabe80d1badde5236e6e6e58315775",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Companies raising guidance, particularly on the earnings front, always deserve some level of attention from investors. Recently, JNJ, GM, and ABT have all raised their outlooks.",
                "category": "company",
                "datetime": 1784906100,
                "headline": "Q2 Earnings: Guidance Upgrades Push These 3 Stocks Higher"
              },
              {
                "id": 141007742,
                "url": "https://finnhub.io/api/news?id=1a4bd9a8e927b4e383f7109324d5417675ca77a48f556859be0ac2e47c6b2f72",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "JNJ's Innovative Medicine unit posts strong Q2 growth despite Stelara's patent loss. See what's fueling momentum into H2 2026.",
                "category": "company",
                "datetime": 1784903700,
                "headline": "J&J's Innovative Medicine Unit Proves Its Resilience in Q2"
              },
              {
                "id": 141006317,
                "url": "https://finnhub.io/api/news?id=12cb6ad467a619cc4b1dda5d74bcfebe305f49b91f339fbe7e6c8b6c00d8a48e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "A name that's often ignored by investors due to its limited historic growth is evolving into a solid income-growth prospect.",
                "category": "company",
                "datetime": 1784903700,
                "headline": "This \"Boring\" Dividend King Is Quietly Turning Into a Growth Machine -- and Many Investors Are Missing It"
              },
              {
                "id": 141006418,
                "url": "https://finnhub.io/api/news?id=140a641b3b970824f2d295f86d2c74ac566785dc1512b72217bcc54a2b304405",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The U.S. Food and Drug Administration on Wednesday granted De Novo authorization for Johnson & Johnson’s OTTAVA Robotic Surgical System, marking the regulatory clearance of the world’s first table-integrated soft tissue robotic platform. The marketing clearance encompasses multiple general surgery...",
                "category": "company",
                "datetime": 1784899863,
                "headline": "FDA Approves Johnson & Johnson Table-Integrated OTTAVA Robotic Surgery System"
              },
              {
                "id": 141005276,
                "url": "https://finnhub.io/api/news?id=fce891feb90878c9b568365dc8ab8155bd45866a90ca9d2b3a5d6fc1f72863eb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The robotic surgery leader's shares have pulled back, forcing investors to weigh a solid recovery record against new questions in its most important market.",
                "category": "company",
                "datetime": 1784897252,
                "headline": "Intuitive Surgical Stock Is On Sale, But Is The Growth Story Changing?"
              },
              {
                "id": 141005156,
                "url": "https://finnhub.io/api/news?id=ffd2c2a9406766dbc8d7cff9d7e264aace42953ab8d198bc2b8e577cddd077d7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Fixed-rate bonds cannot outrun inflation over a 25-year retirement, yet most boomers keep reaching for them anyway. Three companies have raised their dividends for between 50 and 70 consecutive years and may offer a more durable solution, though each carries a hidden transition risk that income investors need to weigh.",
                "category": "company",
                "datetime": 1784896215,
                "headline": "3 Dividend Stocks Baby Boomers Should Own for the Rest of Their Lives"
              },
              {
                "id": 141005278,
                "url": "https://finnhub.io/api/news?id=101d57aad953e5f98a330ef27d7ba5c285a1af9a27e27bfc8b6dd584d78b6aa2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "On Tuesday’s episode of CNBC’s Mad Money, Jim Cramer highlighted Kimberly-Clark Corporation (NYSE:KMB) as a defensive holding for investors looking to lock in profits from high-flying technology stocks and reallocate into lower-risk value plays. After years of sluggish price action, Cramer noted that the consumer giant has finally established a stable bottom, anchored by a […]",
                "category": "company",
                "datetime": 1784895731,
                "headline": "Jim Cramer Says Kimberly-Clark’s Acquisition of Kenvue Creates a High-Margin Powerhouse"
              },
              {
                "id": 141005066,
                "url": "https://finnhub.io/api/news?id=9dacf9259e58fd1221029fce5064498f33c276a99b93ce347dbff82166b669fa",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/107429764/image_107429764.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Legend Biotech Corporation stock: strong Carvykti demand lifts Q2 sales; LB2501 CAR-T shows Phase 1 promise. Click for this LEGN update.",
                "category": "company",
                "datetime": 1784886309,
                "headline": "Legend Biotech: Why I'm Ready To Go Long Again"
              },
              {
                "id": 141006409,
                "url": "https://finnhub.io/api/news?id=e1ce78c5a51a944eb62e6a59e63cc3b2a92e6e9f3dc15efba3b36dc07aba88e8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Novo is seeking an injunction that would halt allegedly “misleading” obesity drug ads. Elsewhere, the FDA began reviewing a highly anticipated medicine and a veteran investor landed at an AI startup.",
                "category": "company",
                "datetime": 1784883600,
                "headline": "Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myeloma"
              },
              {
                "id": 141001671,
                "url": "https://finnhub.io/api/news?id=2b3d8469f528d79fb00654c130f687ab423e66a83b114c1d4335fd3db9a5f390",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "J&J’s Ottava clearance knocked Intuitive's shares lower, but recurring revenue and surgeon switching costs suggest the market overreacted.",
                "category": "company",
                "datetime": 1784833972,
                "headline": "J&J Finally Has a Rival to da Vinci. 1 Number in Intuitive Surgical’s Last Quarter Says It Won’t Be Enough to Move the Needle for JNJ Stock."
              },
              {
                "id": 140997116,
                "url": "https://finnhub.io/api/news?id=bc6828dc888b16a18d4634c6b054cfddda83b8c9bd63e85c8a711b2f5a305ff4",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Stay informed about the performance of the dow jones index one hour before the close of the markets on Thursday. Uncover the top gainers and losers in today's session for valuable insights.",
                "category": "company",
                "datetime": 1784833803,
                "headline": "These dow jones stocks are moving in today's session"
              },
              {
                "id": 140997478,
                "url": "https://finnhub.io/api/news?id=1de5038ef073af3ed66423bedc4fc046766610b7dfdc096d519b53d8bc890542",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "If you're looking for more frequent payouts, you can still enjoy the benefits of low fees and broad diversification, thanks to these top monthly dividend ETFs.",
                "category": "company",
                "datetime": 1784827913,
                "headline": "Best Monthly Dividend ETFs for Consistent Income"
              },
              {
                "id": 140995615,
                "url": "https://finnhub.io/api/news?id=2b1f0452b3a057ed6a9cc36b34e4ba342fc311f608df0b5acc4cf4ca752eee72",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Stay informed about the performance of the dow jones index in the middle of the day on Thursday. Uncover the top gainers and losers in today's session for valuable insights.",
                "category": "company",
                "datetime": 1784824804,
                "headline": "What's going on in today's session: dow jones movers"
              },
              {
                "id": 140998074,
                "url": "https://finnhub.io/api/news?id=3c44c743d1bcf2a3d934bc59f7bc8777ff1351e9911e6554c104a544377e0eb8",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/23/Woman-Touching-Stomach-Painful-Suffering.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Analyst initiates a Buy rating on Palisade Bio with an $8 target, highlighting PALI-2108's multi-billion dollar potential in IBD treatment.",
                "category": "company",
                "datetime": 1784815607,
                "headline": "Palisade Bio Draws Bullish Call, Lead IBD Drug Advances Toward Phase 2"
              },
              {
                "id": 140996248,
                "url": "https://finnhub.io/api/news?id=d79a92d059cad5703142a835ff2763e844d94c47b3c52e8a5be7f5bb39a5e428",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2285918278/image_2285918278.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Zevra Therapeutics jumps on FDA Orange Book patent exclusivity to 2041; profitability, cash-rich balance sheet, celiprolol pipeline. Click for more on ZVRA stock.",
                "category": "company",
                "datetime": 1784815020,
                "headline": "Zevra Therapeutics: Worthy Of An Initial Holding"
              },
              {
                "id": 140994646,
                "url": "https://finnhub.io/api/news?id=f128455069eee81b95530f62b343bf3bb525c652a351fbc7f991a20272c72a2a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson's Q2 beat and strong pharma momentum are raising interest in healthcare ETFs with sizable exposure to the company.",
                "category": "company",
                "datetime": 1784813100,
                "headline": "ETFs to Buy Post JNJ's Q2 Earnings Beat & Bullish 2026 Outlook"
              },
              {
                "id": 140993342,
                "url": "https://finnhub.io/api/news?id=3e5112537701d1d11c6dcbe27975b37a9f64ba94d81f255b1b487843afdf4fe0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE: JNJ), a worldwide leader in multiple myeloma therapies, today announced positive topline results from the three-arm investigational Phase 3 MonumenTAL-6 study evaluating TECVAYLI® (teclistamab-cqyv) + TALVEY® (talquetamab-tgvs), a BCMA and GPRC5D dual antigen targeting regimen, and TALVEY® + pomalidomide in adult patients with relapsed or refractory multiple myeloma (RRMM) who received 1 to 4 prior lines of therapy, including an anti-CD38 antibody and lenalidomide.1 The",
                "category": "company",
                "datetime": 1784809800,
                "headline": "TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma"
              },
              {
                "id": 140994622,
                "url": "https://finnhub.io/api/news?id=907f28abe35f979441ffb5b0eba0ee9edf990499605ef84e64f776b74c770b7c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Stocks have spent months shrugging off geopolitical shocks, businesses are transforming to prepare for a more volatile world.",
                "category": "company",
                "datetime": 1784804100,
                "headline": "Trump’s Iran War and Tariffs Are Changing Corporate Strategies"
              },
              {
                "id": 140993227,
                "url": "https://finnhub.io/api/news?id=ce7062302e8402a96306c8c45637bf7a00ed2e04d6ff96634c948fe414e5f316",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "While stocks shrug off oil shocks and global tariff turmoil, businesses are transforming to prepare for a more volatile world.",
                "category": "company",
                "datetime": 1784804100,
                "headline": "Markets Seem Desensitized to Trump’s Iran War and Tariffs but Companies Are Changing in Fundamental Ways"
              },
              {
                "id": 140992107,
                "url": "https://finnhub.io/api/news?id=d973092747c5ab174d35d1df42a960ee3659bcff3437e46029e44d8c3118d114",
                "image": "https://www.chartmill.com/images/uploads/Best_Dividend_500_264px_webp_9524a3945f.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Discover Johnson & Johnson (JNJ): a top dividend stock with a 2.10% yield, 7.68% growth history, and high profitability rating. A balanced pick for reliable income.",
                "category": "company",
                "datetime": 1784803229,
                "headline": "Johnson & Johnson (NYSE:JNJ) Is a Top Dividend Quality Stock for Reliable Income"
              },
              {
                "id": 140991883,
                "url": "https://finnhub.io/api/news?id=479e5cf7910e61ab90a739d2fa57deccce903267d8591b07b6a50d5c2b4d0fa3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Earlier this week, Johnson & Johnson announced that the FDA had granted De Novo authorization for its OTTAVA Robotic Surgical System, a table‑integrated soft tissue platform cleared for a range of general surgery procedures including Roux-en-Y gastric bypass, gastrectomy, cholecystectomy and appendectomy. This authorization makes Johnson & Johnson a new competitor in U.S. soft‑tissue robotic surgery, potentially reshaping procedure choices for hospitals and surgeons that have long relied on...",
                "category": "company",
                "datetime": 1784798020,
                "headline": "Should FDA’s De Novo Nod for OTTAVA Robotic System Require Action From Johnson & Johnson (JNJ) Investors?"
              },
              {
                "id": 140993894,
                "url": "https://finnhub.io/api/news?id=cc6c61fe6d1e1a1fae49aa5ff7dec69b7a05992a9c5c49f6f835e15d6dd2b42d",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced positive topline results from the three-arm investigational Phase 3 MonumenTAL-6 study evaluating TECVAYLI®",
                "category": "company",
                "datetime": 1784795995,
                "headline": "Johnson & Johnson Announces Topline Results From Phase 3 MonumenTAL-6 Study Evaluating TECVAYLI + TALVEY In Adult Patients With Multiple Myeloma; Study Demonstrated Statistically Significant And Clinically Meaningful Improvements In Progression-Free Survival And Overall Survival"
              },
              {
                "id": 140997606,
                "url": "https://finnhub.io/api/news?id=ce69505dde9c2aa7483984a1a158e4307eff9fe773f140fbefc671155f13219d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Generic drugmakers have much thinner margins, and are less interested in “reshoring” to the US where the costs are higher.",
                "category": "company",
                "datetime": 1784779260,
                "headline": "Trump’s 100% Tariffs on Generic Meds Threaten Headaches at Drugstore Checkouts"
              },
              {
                "id": 140990421,
                "url": "https://finnhub.io/api/news?id=047e681965bfd08426680193b957bca32d3e9102ba561524161f9a1d4deeb9b0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Investors reacted to enterprise spending delays, healthcare competition, and weakening consumer demand.",
                "category": "company",
                "datetime": 1784777466,
                "headline": "Why Did PEGA, ISRG, MCD Stocks Plunge To 52-Week Lows Today?"
              },
              {
                "id": 140990422,
                "url": "https://finnhub.io/api/news?id=81fd8a8980d831085dda3c60ed3a64b3c1537b74a859dad13bb7fc26bc5d0a01",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Intuitive Surgical stock sinks as FDA announces marketing authorization for Johnson & Johnson’s Ottava platform. Here’s why the news is largely bearish for ISRG shares.",
                "category": "company",
                "datetime": 1784752362,
                "headline": "Why Johnson & Johnson Is Sending Intuitive Surgical (ISRG) Stock Down Today"
              },
              {
                "id": 140984721,
                "url": "https://finnhub.io/api/news?id=a13c31f2ca7a17cbdb44673ee3c85c3060b31c53559d522b6d7a2d88928cab6b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "While not disclosing a specific launch timeframe, with de novo clearance in hand, J&J initially plans to launch Ottava with “select customers”.",
                "category": "company",
                "datetime": 1784738350,
                "headline": "J&J MedTech jumps into surgical robot game as OTTAVA secures FDA nod"
              },
              {
                "id": 140984722,
                "url": "https://finnhub.io/api/news?id=eb4380e4b81ff41df4f41f4d09a834efdf3a51fc5ecc7ebde526712ba4b692b7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Intuitive Surgical's growth rests on da Vinci 5, Ion, SP and digital tools as recurring revenue rises and procedure risks persist.",
                "category": "company",
                "datetime": 1784736300,
                "headline": "ISRG Growth Story Hinges on Da Vinci 5, Ion and Recurring Revenue"
              },
              {
                "id": 140984723,
                "url": "https://finnhub.io/api/news?id=b43dd450ad337f594f3885cf44a2dfe69b42d47cc6c24474b47251767859f188",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "ISRG's growth is fueled by robotic surgery, Ion lung biopsy and AI tools, while tariffs, product mix and softer demand pressure margins.",
                "category": "company",
                "datetime": 1784736240,
                "headline": "ISRG Trends Point to AI, Lung Biopsy Growth and Margin Pressure"
              },
              {
                "id": 140984724,
                "url": "https://finnhub.io/api/news?id=b815e8f186230069c844603013fcb9e7af4852d0d473a0021673777909f3f8df",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "ISRG's strong procedure growth, recurring revenue and cash position support its case, but tariffs, mix shifts and placement risks cloud the outlook.",
                "category": "company",
                "datetime": 1784736180,
                "headline": "Is ISRG Stock Worth Buying as Growth Stays Strong but Risks Rise"
              },
              {
                "id": 140984725,
                "url": "https://finnhub.io/api/news?id=b5b7b606303ea11c39254d66783410e7e0eab7130a80773a858aa8724f3ea01b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.",
                "category": "company",
                "datetime": 1784735103,
                "headline": "Are You Looking for a High-Growth Dividend Stock?"
              },
              {
                "id": 140981764,
                "url": "https://finnhub.io/api/news?id=fe4752d3fa507f1a71bb2fbc30af30104fbf8a525645ed5a3e73ad0ec80ed866",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "A pharmaceutical giant is on an incredible run fueled by blockbuster drugs, forcing investors to ask if the price of admission already accounts for the entire victory lap.",
                "category": "company",
                "datetime": 1784726247,
                "headline": "LLY Has Momentum. The Question Is The Price"
              },
              {
                "id": 140983038,
                "url": "https://finnhub.io/api/news?id=af342790192e7316a463a5090eb0e7bb7be2a834da8d153ed2ff10848da12fdc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.",
                "category": "company",
                "datetime": 1784725205,
                "headline": "Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know"
              },
              {
                "id": 140981795,
                "url": "https://finnhub.io/api/news?id=3ba1d70465d2d304236b3d43b6d8d900ae16e7215652ec563e417a5d0159be3b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Connecticut Innovations (CI), the state's strategic venture capital arm, today announced a record-breaking fiscal year, generating $66.5 million in cash proceeds from a series of landmark portfolio exits and a combined $76.1 million from all investment activities. CI invested $59.3 million in 75 early-stage companies and venture funds during the fiscal year ending June 30, 2026, with those deals leveraging an additional $1.2 billion in outside capital.",
                "category": "company",
                "datetime": 1784725200,
                "headline": "Connecticut Innovations Generates Record $66.5 Million in Proceeds in FY2026"
              },
              {
                "id": 140981796,
                "url": "https://finnhub.io/api/news?id=51341f17d0269da48d19702712dcc37965750ed345119a22ad1103ff48ab6628",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Liquidia's Yutrepia is driving strong growth with rapid commercial adoption as the company expands its pipeline and competes in the evolving PAH market.",
                "category": "company",
                "datetime": 1784723760,
                "headline": "Can LQDA's Differentiated PAH Strategy Drive Long-Term Growth?"
              },
              {
                "id": 140983039,
                "url": "https://finnhub.io/api/news?id=3af468cbae481110ca71e4daaf0b3848b3cb86aca78ef879769dc79ed3241107",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson said on Wednesday the U.S. Food and Drug Administration had granted marketing authorization for its robotic surgery ‌device, as the healthcare conglomerate enters the soft-tissue robotic surgery market.  The decision ‌marks a key step for J&J's medtech business that had been seeking to compete in the robotic-assisted ​surgery market, currently dominated by Intuitive Surgical's da Vinci system.  Medtronic's Hugo robot was also approved last year.",
                "category": "company",
                "datetime": 1784719310,
                "headline": "J&J enters US robotic surgery market after device gets marketing authorization"
              },
              {
                "id": 140980995,
                "url": "https://finnhub.io/api/news?id=9f31bc6f86a6cc83697b8caa1dad493b56ddbcc8e5c0f9a1cf4cc9e68c195b86",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "NEW BRUNSWICK, N.J., July 22, 2026--Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has granted De Novo authorization for the OTTAVA™ Robotic Surgical System, the world’s first table-integrated soft tissue robotic system. The system received marketing authorization for multiple procedures in general surgery, including Roux-en-Y gastric bypass, gastrectomy, cholecystectomy, splenectomy, gastric sleeve, small bowel resection, appendectomy, lysis of adhesions, fun",
                "category": "company",
                "datetime": 1784718000,
                "headline": "Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System"
              },
              {
                "id": 140984726,
                "url": "https://finnhub.io/api/news?id=b007f8436b6a97262a650356dc317c7c77e8620d53a9fd7822da3e4e79f99ca5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "While Johnson & Johnson will go head to head with Intuitive in the U.S., analysts questioned whether its robotic surgery system will take meaningful share from the market leader.",
                "category": "company",
                "datetime": 1784717586,
                "headline": "J&J gets FDA authorization for Ottava robot, teeing up competition with Intuitive"
              },
              {
                "id": 140980996,
                "url": "https://finnhub.io/api/news?id=6402c92c6150025f885e084202c1bab0532dca40ce6b9079c4673f8507f71fed",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "WIXOM, Mich., July 22, 2026--Brian Cox joins Rockwell Medical as VP, Quality and Regulatory Compliance, bringing more than 20 years' healthcare experience to the Company.",
                "category": "company",
                "datetime": 1784714400,
                "headline": "Rockwell Medical Advances Quality and Regulatory Leadership"
              },
              {
                "id": 140981615,
                "url": "https://finnhub.io/api/news?id=2f9c9575c82c8b7e73a95c3d96d13cfe3411bbcca5359a37a0a5341a439fca83",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2196897625/image_2196897625.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "The Voya Global Equity Dividend and Premium Opportunity Fund blends high current income with equity exposure. Read more on IGD CEF here.",
                "category": "company",
                "datetime": 1784713300,
                "headline": "IGD: Attractive Yield, But Discount Is Smaller Than Normal"
              },
              {
                "id": 140987702,
                "url": "https://finnhub.io/api/news?id=136b167322d2eca0a36f07982005e78be1cd0a6810384bcceb18d98c3778b21a",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "The system received marketing authorization for multiple procedures in general surgery, including Roux-en-Y gastric bypass, gastrectomy, cholecystectomy, splenectomy, gastric sleeve, small bowel resection, appendectomy,",
                "category": "company",
                "datetime": 1784704603,
                "headline": "Johnson & Johnson Receives FDA De Novo Authorization For Its OTTAVA Robotic Surgical System"
              },
              {
                "id": 140978430,
                "url": "https://finnhub.io/api/news?id=11bf2dccdb7048d386cdf69f80cd417cbba115f2f144d149c1660b23596f7d91",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (JNJ) has declared a third quarter 2026 cash dividend of $1.34 per share, providing income focused investors with fresh information on the stock’s current payout profile and upcoming key dates. See our latest analysis for Johnson & Johnson. The latest dividend announcement comes shortly after Johnson & Johnson reported second quarter 2026 results, raised full year sales guidance to US$100.8b to US$101.4b, and secured FDA approval for its dual energy THERMOCOOL SMARTTOUCH SF...",
                "category": "company",
                "datetime": 1784679524,
                "headline": "Johnson & Johnson (JNJ) Raised Its Dividend, Where Does Fair Value Sit?"
              },
              {
                "id": 140983640,
                "url": "https://finnhub.io/api/news?id=be232ffd5f24c370e540bfb5a76468eb8bccb5950f42060db323284f869a8881",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/22/Washington-D-c---Usa---February-4--2025-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Trump says imported generic drugs face 0% tariffs for 2 years, before 100% and then 200% duties.",
                "category": "company",
                "datetime": 1784671990,
                "headline": "Trump Sets August 1 Start for Generic Drug Tariff Clock, Warns of 200% Duties: Companies Must 'Build Plant and Equipment' in US"
              },
              {
                "id": 140976349,
                "url": "https://finnhub.io/api/news?id=82d9525d03dbe9eedcd561c6aff3946e429bd9bd996312bd1f19747ca485afce",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Management lifted its profit outlook, and investors have more than quadrupled that bet. The question now is what they're really paying for.",
                "category": "company",
                "datetime": 1784664282,
                "headline": "Eli Lilly Stock And The Price Of Confidence"
              },
              {
                "id": 140974912,
                "url": "https://finnhub.io/api/news?id=bbdead80568b813174817288369cedcdbc1558cbe69a3fa5d808987e69a9b82d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The market is offering a steep discount on this medical device maker, but the price tag comes with a story about slowing growth. Here’s how to read it.",
                "category": "company",
                "datetime": 1784660157,
                "headline": "Why BSX Stock Hands You So Much Cash Right Now"
              },
              {
                "id": 140974913,
                "url": "https://finnhub.io/api/news?id=aa203e7f28d79433427fb12950820e559672ed5b69c0e2a20f702bef68a97fcc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "At $353, Intuitive Surgical (ISRG) is being priced to deliver 14.1% revenue growth annually for the next 4 years simply to defend today's 42.1x multiple. That sits below the 21% the business is currently growing at, which is the unusual part. The multiple has already priced in a slowdown that has not yet appeared.",
                "category": "company",
                "datetime": 1784659383,
                "headline": "ISRG Stock: The Math Hidden In Its Price"
              },
              {
                "id": 140974897,
                "url": "https://finnhub.io/api/news?id=4527046ec46f67e07022ec64ce36d30476070db35309a16067f492a6176d2f66",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "This pharma giant is grabbing headlines, but its real value for your portfolio lies in how it moves on the market's worst days.",
                "category": "company",
                "datetime": 1784658705,
                "headline": "AbbVie Stock Zigs When The Market Zags"
              },
              {
                "id": 140973269,
                "url": "https://finnhub.io/api/news?id=5ebe2d0d061ee992e8b81faa547161aa156188af914c5d603050ed0d9e91fad7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The head and neck squamous cell carcinoma market is experiencing significant growth, driven by the rising incidence of head and neck cancers worldwide, increasing adoption of immunotherapies, targeted therapies, and combination treatment approaches. Additionally, the expected launch of emerging therapies such as Amivantamab (RYBREVANT) (Johnson & Johnson), BNT113 (BioNTech), Petosemtamab (MCLA-158) (Genmab), Eftilagimod Alfa (Immutep), and others will further propel the market growth.New York, U",
                "category": "company",
                "datetime": 1784653200,
                "headline": "Correction: Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight"
              },
              {
                "id": 140972633,
                "url": "https://finnhub.io/api/news?id=84e014f7731953bd7829bfc0ad7dc079f0d6754d329df7ff4d1a508919d5026f",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Curious about the dow jones stocks that are in motion on Tuesday? Join us as we explore the top movers within the dow jones index during today's session.",
                "category": "company",
                "datetime": 1784652003,
                "headline": "Which dow jones stocks are moving on Tuesday?"
              },
              {
                "id": 140971473,
                "url": "https://finnhub.io/api/news?id=b128ec3cee87a063d5a49088b82bbd71d52e3598fc8695ab7550deeaf60443c0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "JNJ is pruning its portfolio while Abbott just dropped $21 billion to expand into cancer diagnostics, and the two strategies are pulling their stocks in completely opposite directions. Which move looks smarter when you dig into the actual earnings?",
                "category": "company",
                "datetime": 1784646039,
                "headline": "Johnson & Johnson vs Abbott Laboratories: Two Healthcare Giants on Opposite Trajectories"
              },
              {
                "id": 140971589,
                "url": "https://finnhub.io/api/news?id=6e9cb60560ec50a9dc2a5e4ff31cabd7f9a7b79b6c11da15cec0d4eda37c4146",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Halozyme grants ENHANZE rights to Incyte for developing subcutaneous cancer therapy formulations, aiming to improve treatment convenience for patients.",
                "category": "company",
                "datetime": 1784644680,
                "headline": "HALO Inks Deal With INCY to Support Cancer Therapy Development"
              },
              {
                "id": 140971590,
                "url": "https://finnhub.io/api/news?id=bf3be5c4aadc5bb0bd972cfa359c3c94ff40f39adcdba75fb3284460badcd206",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Seventy companies have raised their dividends through every recession and rate shock for at least a quarter century, but a bruising few quarters for some of NOBL's most-watched names put that unbroken record under real pressure heading into mid-2026.",
                "category": "company",
                "datetime": 1784642575,
                "headline": "70 Dividend Aristocrats Face Their Mid-2026 Test: NOBL’s 2% Yield Under Pressure"
              },
              {
                "id": 140970443,
                "url": "https://finnhub.io/api/news?id=c16cb7492dd2fe661f9ecf0214d921f3c009cf7fdd70e16f5dd383f871bc466f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "eXeX, the global Surgery Intelligence company, today announced the appointment of Max Reinhardt as President, Healthcare. Reinhardt, who has held senior leadership roles in MedTech and pharmaceuticals, will drive the company's commercial execution, bringing Surgery Intelligence into hospital systems across the United States, the United Kingdom, and beyond.",
                "category": "company",
                "datetime": 1784638800,
                "headline": "MedTech Pioneer Max Reinhardt Joins eXeX to Drive Canopus Platform Growth"
              },
              {
                "id": 140968909,
                "url": "https://finnhub.io/api/news?id=66900d2496d7d62427385dac2b48e61ca822d10f397ca17194674abb3f1a3a03",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson, Lam Research and Seagate lead today's analyst picks as strong results, AI demand and growth outlooks drive the latest research.",
                "category": "company",
                "datetime": 1784619540,
                "headline": "The Zacks Analyst Blog Highlights Johnson & Johnson, Lam Research, Seagate, KVH Industries and Dawson Geophysical"
              },
              {
                "id": 140967453,
                "url": "https://finnhub.io/api/news?id=71d152747a124f650547e49559e52976f82ea03fbbd25e53f37829d152156f70",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "One of Rhode Island's most-wanted fugitives was captured Monday after apparently hiding out for 20 years as a biotech executive.",
                "category": "company",
                "datetime": 1784599220,
                "headline": "Straight Out Of A Soap Opera: Biotech Exec Arrested After 21 Years On The Run"
              },
              {
                "id": 140964880,
                "url": "https://finnhub.io/api/news?id=12a8abdbc76bf7f5d75a741fcb8bf92b1169e627404cdd9748c5e4427653cfaf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson beat Q2 estimates as growth in key drugs, MedTech and its pipeline helps offset Stelara headwinds. Read what's driving outlook.",
                "category": "company",
                "datetime": 1784578140,
                "headline": "Top Analyst Reports for Johnson & Johnson, Lam Research & Seagate"
              },
              {
                "id": 140963421,
                "url": "https://finnhub.io/api/news?id=6ea0dd033658292f48582a592a40caa31066d357172a543dd20d199c2861cc74",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "You can be forgiven for doing a double-take on Intuitive Surgical (ISRG) on Friday. The company posted second-quarter revenue of $2.89 billion, up 19% from a year ago and comfortably ahead of Wall Street estimates. Yet the stock ended the day down 14.1%, closing at a new 52-week low.",
                "category": "company",
                "datetime": 1784574905,
                "headline": "The Robot Maker's Paradox"
              },
              {
                "id": 140962978,
                "url": "https://finnhub.io/api/news?id=02b2e30e4b5a8015da142e1b9a1f892637cc927d311f40cc472a5668f9bca33d",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Curious about the top performers within the dow jones index one hour before the close of the markets on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.",
                "category": "company",
                "datetime": 1784574604,
                "headline": "Stay informed with the top movers within the dow jones index on Monday."
              },
              {
                "id": 140963403,
                "url": "https://finnhub.io/api/news?id=f4884d142c8fe4723c200af3df0c71c73b1c873e2c314a7447d92ad950c86ede",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The healthcare giant's pharma division is booming, but analysts on its latest call wanted to know if that's enough to cover for a sudden slowdown in MedTech.",
                "category": "company",
                "datetime": 1784573756,
                "headline": "Reading Between The Lines Of JNJ Stock's Latest Call"
              },
              {
                "id": 140963423,
                "url": "https://finnhub.io/api/news?id=26047126ae59bd8c4eb72c217ec847dd194744894cd020aa98db1bbb6da3a19e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The surgical robotics giant beat estimates, but a moderation in its core US market has investors questioning the whole story.",
                "category": "company",
                "datetime": 1784571665,
                "headline": "What's More Important For Intuitive Surgical: Today's Robots Or Tomorrow's Growth?"
              },
              {
                "id": 140963424,
                "url": "https://finnhub.io/api/news?id=589a1dde19072b6d106740e598d7398a3c273b730e0ffb276308b41b42040853",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Jim Cramer took a bullish stance on Alibaba despite its brutal year-to-date slide, pairing the call with two steady compounders he thinks belong in every long-term portfolio. Here is what he told one caller sitting on a sizable BABA position.",
                "category": "company",
                "datetime": 1784570231,
                "headline": "Jim Cramer: Alibaba Is “Still the Best Way to Play China” Despite Being Down 18% YTD"
              },
              {
                "id": 140971579,
                "url": "https://finnhub.io/api/news?id=b34dab5f1189ce264bb943480be0297ade22fedb65a81a841f4d005657c7a48b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "While AI stocks correct, Johnson & Johnson, Altria, Coca-Cola, JPMorgan, and Apple are quietly trading near 52-week or all-time highs ahead of earnings.",
                "category": "company",
                "datetime": 1784561100,
                "headline": "5 Stocks Quietly Trading Near All-Time Highs While Everyone Watches the AI Drama"
              },
              {
                "id": 140960594,
                "url": "https://finnhub.io/api/news?id=b6dc2875bc5307f0ba48199fbd747c6354cd7ce2ee06b8136a7e109730aa2ede",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "JNJ raised its 2026 outlook after strong Q2 results, but can new medicines and pipeline strength outweigh patent losses and MedTech challenges?",
                "category": "company",
                "datetime": 1784551980,
                "headline": "Should You Buy, Sell or Hold J&J's Stock Post a Robust Q2 Performance?"
              },
              {
                "id": 140959509,
                "url": "https://finnhub.io/api/news?id=c8528b8311704302ec45b4ffa65ff0f68ee49d76d3993cfcb752857c60ab52b6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "LQDA, BILL and Colgate-Palmolive highlight recent Zacks picks as multiple portfolios outperformed or posted strong stock gains despite market volatility.",
                "category": "company",
                "datetime": 1784550840,
                "headline": "Beat the Market the Zacks Way: Liquidia, BILL, Colgate-Palmolive in Focus"
              },
              {
                "id": 140959510,
                "url": "https://finnhub.io/api/news?id=a9c2ac51c5f6093a7eef3814a52242e894c9058def09703ffad12d8ef3fb6476",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "For many cancers now, the standard treatment is chemotherapy plus an immunotherapy such as  Merck  Keytruda, the best-selling drug in the world.  Many think it will pair two innovations: precisely-targeted chemo drugs known as antibody-drug conjugates, or ADCs, and augmented immunotherapies in the form of bispecific antibodies.  Bispecific antibodies are being tested by  Bristol Myers Squibb  (with its partner  BioNTech  ),  AstraZeneca  and the biotech firm  Summit Therapeutics  ADCs have already rung up big sales for Astra,  Pfizer Gilead Sciences  and  Roche Holding  but Merck has a strong contender in development.",
                "category": "company",
                "datetime": 1784549820,
                "headline": "Merck’s Keytruda Faces a Patent Cliff. These New Cancer Drugs Could Take Over."
              },
              {
                "id": 140958951,
                "url": "https://finnhub.io/api/news?id=5ed9acc8832a619e0dcafb8eca77d97a1e2404577fca62c7969d2a1bbc22ad55",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2194222148/image_2194222148.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "ImmunityBio (IBRX) cautious buy: Anktiva shows strong NMIBC results and pipeline upside, but valuation, dilution and cash burn raise risk—read now.",
                "category": "company",
                "datetime": 1784536225,
                "headline": "ImmunityBio: Revisiting My Bearish Call After A Strong Rally (Rating Upgrade)"
              },
              {
                "id": 140958130,
                "url": "https://finnhub.io/api/news?id=ec6706319150549ddafa63e0a3db84a31d57f725ac1deda3893c213e428ab5e8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Despite its enticing dividend yield and relatively attractive valuation, J&J Snack Foods' (JJSF) stock may represent a value trap.",
                "category": "company",
                "datetime": 1784534400,
                "headline": "Bear of the Day: J&J Snack Foods (JJSF)"
              },
              {
                "id": 140957651,
                "url": "https://finnhub.io/api/news?id=b48119d669b046cb291e67f2f812348161794131c0b00f6b915027443a57822d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "For many cancers now, the standard treatment is chemotherapy plus an immunotherapy such as  Merck  Keytruda, the best-selling drug in the world.  Many think it will pair two innovations: precisely-targeted chemo drugs known as antibody-drug conjugates, or ADCs, and augmented immunotherapies in the form of bispecific antibodies.  Bispecific antibodies are being tested by  Bristol Myers Squibb  (with its partner  BioNTech  ),  AstraZeneca  and the biotech firm  Summit Therapeutics  ADCs have already rung up big sales for Astra,  Pfizer Gilead Sciences  and  Roche Holding  but Merck has a strong contender in development.",
                "category": "company",
                "datetime": 1784527200,
                "headline": "What Comes After Merck’s Keytruda? The Race for the Next Standard Cancer Treatment."
              },
              {
                "id": 140955522,
                "url": "https://finnhub.io/api/news?id=8d88b130ffa95c1632bba1a2a2e600b109439fdb1e85c0c8ffa6f37540cd5258",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "J&J has more than 28 sources of blockbuster revenue.",
                "category": "company",
                "datetime": 1784500200,
                "headline": "Is It Too Late to Buy Johnson & Johnson After Its Blowout Earnings Report?"
              },
              {
                "id": 140954711,
                "url": "https://finnhub.io/api/news?id=bd7f9275f6da066da0e062bbc8c0c2967aae456c9c00c3c32cd0ef0849b285c8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "They can help stabilize your portfolio in these otherwise volatile times.",
                "category": "company",
                "datetime": 1784492400,
                "headline": "My 2 Favorite Dividend Kings to Buy Right Now"
              },
              {
                "id": 140953052,
                "url": "https://finnhub.io/api/news?id=67eeee0773b2fcf0a7f7695994ba789e51fa6c55cddd961ffbccaed06e0cc8b2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "DePuy Synthes, part of Johnson & Johnson MedTech, has acquired spine surgery company Expanding Innovations, adding new expandable interbody technologies to its portfolio. Johnson & Johnson has received FDA approval for its Dual Energy THERMOCOOL SMARTTOUCH SF Platform in electrophysiology, expanding its ablation technology offering. For investors watching Johnson & Johnson, ticker NYSE:JNJ, these MedTech moves arrive with the stock at $253.04 and a value_score of 2. The company has recorded...",
                "category": "company",
                "datetime": 1784477270,
                "headline": "Johnson & Johnson (JNJ) Buys Spine Tech And Wins FDA Nod For Heart Device"
              },
              {
                "id": 140951671,
                "url": "https://finnhub.io/api/news?id=edcfdddd5026455494e57595a336d293ee28d8d9a3b6d45f94f6c9f02447669b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "All three pharma giants have left the S&P 500 in the dust, but surging returns and strong fundamentals tell very different stories about where each stock goes from here.",
                "category": "company",
                "datetime": 1784467858,
                "headline": "3 Biggest Pharma Giants: Buy, Sell or Hold?"
              },
              {
                "id": 140951727,
                "url": "https://finnhub.io/api/news?id=4ae5fefce3d887eea60615731dbad10a3cf82c75257323d81f2e4c81c3a0cde3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "A portfolio paying $55,000 this year feels useful today, but inflation has a way of quietly making that same paycheck feel smaller every year you spend it. The yield you choose right now could either protect your retirement income or slowly hollow it out.",
                "category": "company",
                "datetime": 1784466389,
                "headline": "Would You Rather Earn $55,000 Today or $110,000 in 20 Years?"
              },
              {
                "id": 140951073,
                "url": "https://finnhub.io/api/news?id=fafc6aeb110fdd02064f73a91ea365091609ea30e4fb379d6dcb9508affe1c6d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Most investors chase the biggest dividend check they can find today, but that instinct quietly sabotages the income they could be collecting a decade from now. The math behind a smarter approach is almost offensively simple once you see it.",
                "category": "company",
                "datetime": 1784458843,
                "headline": "From a $38,000 Income to $84,000 Without Investing Another Dollar"
              },
              {
                "id": 140950551,
                "url": "https://finnhub.io/api/news?id=f01b55cce75788117c7e394aa1e666da2acbea913eccbbe07be2af1e72923c65",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Headline inflation keeps rising faster than Social Security adjustments, quietly shrinking what retirement actually buys. A small, dedicated portfolio sleeve could fund those annual increases entirely from income, but the tier you choose changes everything about how much capital you actually need.",
                "category": "company",
                "datetime": 1784452337,
                "headline": "The Portfolio That Lets You Ignore Inflation"
              },
              {
                "id": 140943803,
                "url": "https://finnhub.io/api/news?id=0dc2c819466c7138315ffa76be796026e4c9152e78e0aa2ecd3903decb24e813",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Most investors chase the biggest yield they can find, but the portfolio that actually grows your income year after year is built on a completely different logic. Here is how dividend math quietly delivers something that usually requires a performance review.",
                "category": "company",
                "datetime": 1784387281,
                "headline": "The Portfolio That Gives You a $2,000 Raise Every Year"
              },
              {
                "id": 140943075,
                "url": "https://finnhub.io/api/news?id=967d9cb8efa721530bf134eb3b72fb54af112a8dce5b14647ab21b605e484810",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Every new tariff headline, rate decision, and earnings miss seems to demand a financial response, and that constant pressure is exhausting. There is a way to build a portfolio so sturdy that the daily news cycle loses its grip on your nerves.",
                "category": "company",
                "datetime": 1784379647,
                "headline": "The Portfolio That Lets You Cruise Through the News, Unbothered"
              },
              {
                "id": 140943050,
                "url": "https://finnhub.io/api/news?id=b6726c67b6d318f590ea801e8e23e38a41d664def7724f009c1732cc043834e1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "July has a long history of punishing investors who mistake a good run for a durable business. Three Dividend Kings have kept raising their payouts through every major crash since 1987, and all three just delivered beat-and-raise quarters heading into a summer that already feels shaky.",
                "category": "company",
                "datetime": 1784376045,
                "headline": "3 Dividend Stocks That Have Survived Every Market Crash in July"
              },
              {
                "id": 140942415,
                "url": "https://finnhub.io/api/news?id=c189e19fb9e0837e2ced094a748f8a447c86c96f6cd670336ac539cab7f21005",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Lifelong learning sounds like a noble habit until you price it out across decades and realize it behaves more like a recurring expense than a one-time splurge. The portfolio that funds it may look nothing like the obvious choice.",
                "category": "company",
                "datetime": 1784373097,
                "headline": "Here’s the Funding It Takes to Keep Learning Forever"
              },
              {
                "id": 140951072,
                "url": "https://finnhub.io/api/news?id=73534d700060689b3f3e12bb0a8fd766db23bf8c5f3b1546e2cec50941fb3bf1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "A tech selloff hit the S&P 500 and NASDAQ this week while energy and financial stocks gained; MarketBeat analysts recap Micron, Netflix, Broadcom, Apple and more ahead of Alphabet's earnings.",
                "category": "company",
                "datetime": 1784372400,
                "headline": "MarketBeat Week in Review – 07/13- 07/17"
              },
              {
                "id": 140939403,
                "url": "https://finnhub.io/api/news?id=57d40fe7bb5c8aac6f79be0256a9f813474876b809b4a24f9b6e6987567d036e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "DIVO's covered-call strategy looks solid on paper, but two macro forces are quietly working against its monthly payouts in ways most income investors overlook. Here is what the options chain and the Treasury market are signaling right now.",
                "category": "company",
                "datetime": 1784333456,
                "headline": "If Volatility Stays Low, Here’s What Happens to DIVO’s Monthly Income"
              },
              {
                "id": 140939163,
                "url": "https://finnhub.io/api/news?id=2b7e563ff687d8cc979d3783bccd33f2bf9feb60d528dbd963b372e93e4735fb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The healthcare giant's stock jump was about more than an earnings beat, offering proof of a growth story broader and more resilient than you thought.",
                "category": "company",
                "datetime": 1784328964,
                "headline": "Abbott Just Showed Its Growth Engine Has More Than One Cylinder"
              },
              {
                "id": 140939161,
                "url": "https://finnhub.io/api/news?id=f57b9ce7b4402974f3ad4605a0ce95da73880c2e007cc7fb1d99cb560f207f71",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The drugmaker looks expensive today, but the real story is what you are actually paying for the earnings of tomorrow.",
                "category": "company",
                "datetime": 1784325063,
                "headline": "The Real Question Buried Inside Merck Stock's Premium Price"
              },
              {
                "id": 140937906,
                "url": "https://finnhub.io/api/news?id=a0e0cf5d5229803aafd81bc10762576800986410f1c10defc757f88a1be078dd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Jim Cramer named five blue-chip stocks the market punished after strong earnings, and he's betting that millions of investors and billions of dollars got it completely wrong.",
                "category": "company",
                "datetime": 1784322864,
                "headline": "Jim Cramer Says the Market Is “Dead Wrong” About These 5 Oversold Stocks"
              },
              {
                "id": 140937907,
                "url": "https://finnhub.io/api/news?id=544c9a5b6ab515dd6fe654dd847834a8214c9a346b18b078ca02fbcb4330a814",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Cramer named specific sectors he's betting on for late 2026 while calling out two popular investments as traps that investors should exit now, regardless of where they bought in.",
                "category": "company",
                "datetime": 1784322800,
                "headline": "Jim Cramer Says Oracle Is “Going Down” and Avoid Every Liquor Stock. Here’s What He’d Buy Instead"
              },
              {
                "id": 140936306,
                "url": "https://finnhub.io/api/news?id=9379fd9a229dde89bca8d1d8f41d09e6f5b887ee5f712f95edadbe7a94d281c2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "DGRO's next index rebalance could quietly shift millions of dollars across healthcare and financials, and one overlooked holding sits at the center of the trade. Here is why the December reconstitution deserves more attention than investors are giving it.",
                "category": "company",
                "datetime": 1784315450,
                "headline": "DGRO’s December Rebalance Could Reshape Healthcare Exposure: Here’s What to Watch"
              },
              {
                "id": 140934459,
                "url": "https://finnhub.io/api/news?id=a2ee62a66c63a946d94c3e6beb499c40b3125181a2923f5fa2fc732d6e9e4955",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "With 10-year Treasuries near 4.62%, VYM's $94.6 billion portfolio faces a real test from risk-free yields, and two familiar names inside the fund are quietly raising red flags about future income growth.",
                "category": "company",
                "datetime": 1784307459,
                "headline": "VYM’s $94.6 Billion Portfolio Beats Treasury Yields with Dividend Kings Leading the Way"
              },
              {
                "id": 140933705,
                "url": "https://finnhub.io/api/news?id=cf957e631b08afbc352ac0c9645261668019b12720ed7857cae855b3ae4f2250",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Stay informed about the performance of the dow jones index in the middle of the day on Friday. Uncover the top gainers and losers in today's session for valuable insights.",
                "category": "company",
                "datetime": 1784306404,
                "headline": "Top dow jones movers in Friday's session"
              },
              {
                "id": 140933340,
                "url": "https://finnhub.io/api/news?id=dc6646e28e14b3fdaff43894e8f7f8bbb22af0391c056fc946d02d9e5a21b04b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "SPYI's 12% annualized payout looks generous until you check what two converging macro forces are quietly doing to the premium engine that funds it.",
                "category": "company",
                "datetime": 1784304654,
                "headline": "SPYI Investors: Watch These 2 Macro Factors Before the Next Distribution"
              },
              {
                "id": 140932972,
                "url": "https://finnhub.io/api/news?id=88bacf0e7e75d7ad7490cf737b97af9956511d5def5cdbef0d549d91e59d52d9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Four thousand dollars a month can cover a paid-off house, groceries, utilities, insurance, and modest travel in many parts of the country. It is also more than the $3,208 average monthly Social Security benefit SSA estimates for an aged couple, both receiving benefits, in January 2026. A portfolio producing another $4,000 a month can materially ... Can a Conservative Portfolio Really Generate $4,000 a Month in Retirement Income?",
                "category": "company",
                "datetime": 1784302670,
                "headline": "Can a Conservative Portfolio Really Generate $4,000 a Month in Retirement Income?"
              },
              {
                "id": 140932973,
                "url": "https://finnhub.io/api/news?id=0504e442cf7f265bb43b0e44d54c0386af3ed0aa7fd4f592d362e90177bbdfa3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "JNJ beats Q2 estimates and raises 2026 guidance, but shares fall as MedTech misses expectations. Find out what weighed on the unit and what's next.",
                "category": "company",
                "datetime": 1784298660,
                "headline": "J&J Stock Falls Despite Strong Q2 Beat & Higher 2026 View: Here's Why"
              },
              {
                "id": 140931435,
                "url": "https://finnhub.io/api/news?id=43bdff8a716708433fb4dc9ca77c1f32465999080349e9d6bee352b6884763f2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Stock Market Today: The Dow Jones index dropped Friday as Netflix stock plunged on earnings. SpaceX shares sold off on a canceled test flight.",
                "category": "company",
                "datetime": 1784295671,
                "headline": "Stock Market Today: Nasdaq Leads Indexes Down; SpaceX Slides As Flight Canceled (Live Coverage)"
              },
              {
                "id": 140931563,
                "url": "https://finnhub.io/api/news?id=9a8cdb541c3ef9be788480458508c8b7afe3ea54b0f0964b1a39fcf2f3561dab",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "This healthcare giant is forecasting a significant acceleration, but you are being asked to look past a slowdown in its biggest growth engine and other execution hurdles.",
                "category": "company",
                "datetime": 1784290654,
                "headline": "Can Abbott Stock Deliver on Its Second-Half Growth Promise?"
              },
              {
                "id": 140931564,
                "url": "https://finnhub.io/api/news?id=c1f3439f3f31bb5e63491154cf43bcb3dc1f5d6f47086643b3ecba50b2f29e50",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Intuitive Surgical stock falls sharply after earnings, but this analyst believes investors are missing part of the picture.",
                "category": "company",
                "datetime": 1784289180,
                "headline": "Why This Surgical Robot Stock Is Still a Buy During Its Worst Day in 4 Years"
              },
              {
                "id": 140930733,
                "url": "https://finnhub.io/api/news?id=2f16834b08c6c17f3fe26ebf1ea738c1f438efeb6aa48d5eb4eb3ba6a91c9cde",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "A portfolio that pays $27,000 a year in dividends sounds modest. Left alone for a little more than a decade of steady dividend growth, that same income stream can quietly grow toward $66,000 without a single additional dollar of savings. That is the basic appeal of dividend growth investing: the arithmetic of today’s yield matters, ... Growing an Income Tree: From $27,000 to $66,000",
                "category": "company",
                "datetime": 1784286034,
                "headline": "Growing an Income Tree: From $27,000 to $66,000"
              },
              {
                "id": 140934862,
                "url": "https://finnhub.io/api/news?id=9254cbc0007632f41e4f18a578ee59d8ca248cce6c424d6e754fd2559e0baa3e",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Guggenheim  analyst Vamil Divan   reiterates Johnson & Johnson (NYSE:JNJ) with a Buy and maintains $270 price target.",
                "category": "company",
                "datetime": 1784277291,
                "headline": "Guggenheim Reiterates Buy on Johnson & Johnson, Maintains $270 Price Target"
              },
              {
                "id": 140926081,
                "url": "https://finnhub.io/api/news?id=e64f76c09adafa515f4830316766b320a68890737e1611bda2f9562417d8f44b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Citi analysts laid out the appeal of biopharma stocks, with the NYSE Arca Pharmaceutical Index outrunning the S&P in the last month.",
                "category": "company",
                "datetime": 1784236020,
                "headline": "Why Healthcare Stocks Look Like a Haven in This Market"
              },
              {
                "id": 140934035,
                "url": "https://finnhub.io/api/news?id=582214e1504528124d4be9c4af6af3802955bcbb5b2ad89b6f8829dfea0ac010",
                "image": "https://image.cnbcfm.com/api/v1/image/108336317-5ED3-MM-A-BLOCK-071626.jpg?v=1784242037&w=1920&h=1080",
                "source": "CNBC",
                "related": "JNJ",
                "summary": "'Mad Money' host Jim Cramer talks going against the grain in the market.",
                "category": "company",
                "datetime": 1784231304,
                "headline": "Jim Cramer: It takes a lot of guts to disagree with the market about a stock after it reports"
              },
              {
                "id": 140924324,
                "url": "https://finnhub.io/api/news?id=d4761d29e079ca2623b2595a2c5f2d57d077d95edfc51ae51e3148fa11e22d4b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Eli Lilly just wrote a $2.8 billion check on a psychedelic nasal spray that won't have pivotal trial data until 2029, and the reasoning behind that bet reveals where Big Pharma thinks depression treatment is heading.",
                "category": "company",
                "datetime": 1784224421,
                "headline": "Eli Lilly Buys Psychedelics Maker Atai Beckley for $2.8 Billion to Develop DMT-Like Depression Drug"
              },
              {
                "id": 140922631,
                "url": "https://finnhub.io/api/news?id=7b429b088d655c237aac8342e677ff2e6a0d4bbbe45d0f80f410066bf2a7a864",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Few things ruin a Saturday morning faster than the words “your timing chain is going.” Car repair bills arrive unannounced, cost more than expected, and have a way of landing the same week as property taxes or insurance renewals. The fix is a small, dedicated slice of capital whose only job is to absorb those ... The Portfolio That Pays All Your Car Repairs For Life",
                "category": "company",
                "datetime": 1784224058,
                "headline": "The Portfolio That Pays All Your Car Repairs For Life"
              },
              {
                "id": 140924331,
                "url": "https://finnhub.io/api/news?id=2cccc71304a92dbf83c35d1711fa335b36545f9818f085bb547e2a190d5858bd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "ABBV's neuroscience business is expected to post solid Q2 growth, with key brands and Vyalev in focus ahead of earnings on July 31.",
                "category": "company",
                "datetime": 1784222460,
                "headline": "Will AbbVie's Neuroscience Franchise Deliver Another Strong Quarter?"
              },
              {
                "id": 140922632,
                "url": "https://finnhub.io/api/news?id=7c29be2f94767e0c8e1e1ad8878c710d0617b7fa7550c65b0b37d527287ef6d8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Q2 earnings are off to a strong start. Tech, Energy, Materials, Finance and Aerospace ETFs could shine as profit growth broadens across sectors.",
                "category": "company",
                "datetime": 1784218260,
                "headline": "Sector ETFs to Win on Q2 Earnings Growth Potential"
              },
              {
                "id": 140924212,
                "url": "https://finnhub.io/api/news?id=f1a83df4a460a5536afadd68c6d8b67158a8073b9c8875f11b1e6d8dfa1c018b",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2268438699/image_2268438699.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Johnson & Johnson’s strong Q2 earnings, Spravato sales +41%, and raised 2026 EPS guidance. See why this analysis upgrades JNJ from Sell to Hold.",
                "category": "company",
                "datetime": 1784217215,
                "headline": "I Was Wrong About Johnson & Johnson: Upgrading To Hold (Rating Upgrade)"
              },
              {
                "id": 140920971,
                "url": "https://finnhub.io/api/news?id=6eac034c6914e1faa4d3597b25972ecf5df2fdb6a0f3aad2a0291a50be75e185",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Eli Lilly (LLY) is acquiring AtaiBeckley (ATAI) — a biopharmaceutical company that specializes in psychedelic-based mental health treatments — in a new deal valued at up to $3.8 billion. Mizuho Americas healthcare equity strategist Jared Holz weighs in on this deal and what it represents for M&A in the broader pharma space.",
                "category": "company",
                "datetime": 1784216700,
                "headline": "Eli Lilly is acquiring psychedelic drug developer AtaiBeckley for $3.8 billion"
              },
              {
                "id": 140920972,
                "url": "https://finnhub.io/api/news?id=599fd74550f7b98d365d009af33a716949e9a10cb0c48e26cf5ef5e8637d71f5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson's (JNJ) Innovative Medicine segment momentum is building into 2027, with the compa",
                "category": "company",
                "datetime": 1784215796,
                "headline": "Johnson & Johnson's Innovative Medicine Segment Momentum Continues to Build into 2027, RBC Says"
              },
              {
                "id": 140920973,
                "url": "https://finnhub.io/api/news?id=383c8a910d0b53a4d210ac7d5f3ecafa0dbf367b7fec681eb1bd02c4862d419b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Abbott Laboratories posted slightly better-than-expected second-quarter earnings and raised its full-year profit outlook.",
                "category": "company",
                "datetime": 1784212620,
                "headline": "Why Abbott Stock Is Having Its Best Day in 24 Years"
              },
              {
                "id": 140925253,
                "url": "https://finnhub.io/api/news?id=7b55a75cfcff35bfaea03818a622a465035efd6daf3d0186d0f34f068e6f793e",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Raymond James  analyst Jayson Bedford   maintains Johnson & Johnson (NYSE:JNJ) with a Outperform and raises the price target from $258 to $265.",
                "category": "company",
                "datetime": 1784211124,
                "headline": "Raymond James Maintains Outperform on Johnson & Johnson, Raises Price Target to $265"
              },
              {
                "id": 140920962,
                "url": "https://finnhub.io/api/news?id=2cec22579047e245108d6c96f0282da91db225b322b2727f1dee0c8a8a992058",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "One generates steady cash flow with a lower valuation; the other is growing at 45% but carries higher leverage.",
                "category": "company",
                "datetime": 1784210761,
                "headline": "Johnson & Johnson vs. Eli Lilly and: Which Pharma Giant Stock Is a Better Buy in 2026?"
              },
              {
                "id": 140920975,
                "url": "https://finnhub.io/api/news?id=7c8ef675a3c6fa5fb020f15ac8b4d391cda0c47a701fbe8e4984298f9b1e9e13",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson raises its 2026 outlook after Q2 earnings and revenues beat estimates, driven by Innovative Medicine strength and pipeline momentum.",
                "category": "company",
                "datetime": 1784210400,
                "headline": "Johnson & Johnson Raises 2026 Outlook After Q2 Earnings Beat"
              },
              {
                "id": 140920976,
                "url": "https://finnhub.io/api/news?id=76bc23d4d790ded7e25ac854371641c9f43064d0b6f2a5978ce3830dc769912b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Abbott’s (ABT) latest financial disclosure reveals a significant strategic evolution that market participants often overlook amidst the focus on quarterly beats. The company is actively executing a structural pivot, shifting its capital allocation and growth dependency away from the volatile Nutrition segment toward high-margin, innovation-led MedTech and specialized diagnostics.",
                "category": "company",
                "datetime": 1784210345,
                "headline": "Why Abbott Stock Is Reimagining Its Future"
              },
              {
                "id": 140923118,
                "url": "https://finnhub.io/api/news?id=849660181dbdce21c5283300d80d1ffbd4882504fe8ef32a9722935ced89a103",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/16/Konskie--Poland---September-07--2025-Uni.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "UnitedHealth's (UNH) strong earnings and raised outlook lifted healthcare ETFs despite a sharp decline in Medicare Advantage membership.",
                "category": "company",
                "datetime": 1784208257,
                "headline": "UnitedHealth Rally Sparks Bullish Case for Healthcare ETFs Despite Medicare Advantage Losses"
              },
              {
                "id": 140919686,
                "url": "https://finnhub.io/api/news?id=73e8666060b1415c53da17946bd06f234dc80c8765b33ed82a66e02cf0745fc2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "While the market focuses on a single class of blockbuster drugs, a different story is unfolding inside the company. Lilly’s immunology, oncology, and neuroscience medicines are quietly compounding at a blistering pace. These other therapeutic areas collectively grew by 160% last quarter, a rate that suggests a much broader growth engine is taking shape.",
                "category": "company",
                "datetime": 1784207994,
                "headline": "What Could Push LLY Stock Higher From Here?"
              },
              {
                "id": 140919685,
                "url": "https://finnhub.io/api/news?id=8aaaa1ac492f93cd7e2c8a593e3ee9b65133645f1fcce9caf8568dc8cb52f96d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "While many investors focus on a slowdown in one business segment, they may be overlooking the remarkable growth occurring in another.",
                "category": "company",
                "datetime": 1784207994,
                "headline": "The Real Engine Behind Johnson & Johnson Stock's Next Climb"
              },
              {
                "id": 140919720,
                "url": "https://finnhub.io/api/news?id=9d2f9b3f8a8731e901d1e5ad81cf41b276753ec46ea230c1fd3ca2fe7db06730",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The pharma division is firing on all cylinders, but a sudden crack in the MedTech business has the market worried about the company's new two-part growth plan.",
                "category": "company",
                "datetime": 1784205864,
                "headline": "Why Is The Market Punishing JNJ Stock?"
              },
              {
                "id": 140925255,
                "url": "https://finnhub.io/api/news?id=a1e7a18b2666f804b907fee1ef3b62977722ec84865ee61dc95830e221a48894",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/16/Johnson--Johnson.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "The reasons why RBC Capital Markets maintains its stock rating.",
                "category": "company",
                "datetime": 1784203897,
                "headline": "Johnson & Johnson Posts Upbeat Q2: IM Momentum Building Into 2027, Says Bullish Analyst"
              },
              {
                "id": 140919721,
                "url": "https://finnhub.io/api/news?id=6520635232f64f8347ba4e9dff3721065414e7b36bcf1950f94d2c6548cdc023",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "NEW BRUNSWICK, N.J., July 16, 2026--Johnson & Johnson (NYSE: JNJ) today announced with TIME the launch of the Healthcare Champion of the Year. The new branded recognition will honor healthcare professionals in the U.S., selected by Johnson & Johnson and a panel of industry experts, whose care, innovation and grit are driving health system change to advance better care for all.",
                "category": "company",
                "datetime": 1784203860,
                "headline": "Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award"
              },
              {
                "id": 140919722,
                "url": "https://finnhub.io/api/news?id=bd3a772633121acf0452f10ab368b69a562e2c64a485ce99d79a2ec01db57828",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Abbott Laboratories posted slightly better-than-expected second-quarter earnings and raised its full-year profit outlook.",
                "category": "company",
                "datetime": 1784203500,
                "headline": "Why Abbott Earnings Are Sending the Stock Higher"
              },
              {
                "id": 140919723,
                "url": "https://finnhub.io/api/news?id=de8e48f037f5c09136d811016bc9ddf198f5b74d438512b6dacad9fa099e2580",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "RAYNHAM, Mass., July 16, 2026--DePuy Synthes, a global leader in orthopaedic technologies and solutions, today announced it has acquired Expanding Innovations, Inc., an emerging leader in expandable implant technology for spine surgery. The transaction strengthens DePuy Synthes’ Spine portfolio and expands its position in the rapidly growing expandable interbody cage segment.",
                "category": "company",
                "datetime": 1784203200,
                "headline": "DePuy Synthes Acquires Expanding Innovations™"
              },
              {
                "id": 140925256,
                "url": "https://finnhub.io/api/news?id=f6de372db2648d397e31f9942e51ccb26c3dd7374c1db33b16261b2fe74c1950",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "RBC Capital  analyst Shagun Singh   reiterates Johnson & Johnson (NYSE:JNJ) with a Outperform and maintains $287 price target.",
                "category": "company",
                "datetime": 1784199879,
                "headline": "RBC Capital Reiterates Outperform on Johnson & Johnson, Maintains $287 Price Target"
              },
              {
                "id": 140925257,
                "url": "https://finnhub.io/api/news?id=c4ad69c879606e9a3f256389df43bbfaf5fa9660a189217a14842a88cab536dc",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/insider_trade_2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "A report on July 15, 2026 shows that Representative Thomas Kean from New Jersey sale stock in Alphabet (NASDAQ:GOOGL), valued between $26,012 and $215,000. According to the July filing, the transaction occurred on June",
                "category": "company",
                "datetime": 1784199622,
                "headline": "New Jersey Rep. Thomas Kean Sold Over $26K Worth of Alphabet Stock: Here’s What You Should Know"
              },
              {
                "id": 140925258,
                "url": "https://finnhub.io/api/news?id=8bf525878cd1213d29b7dccd45b7fb5e3eb5eb5f9f5d242f48df0f4e450f5507",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Wells Fargo  analyst Larry Biegelsen   maintains Johnson & Johnson (NYSE:JNJ) with a Overweight and raises the price target from $263 to $272.",
                "category": "company",
                "datetime": 1784199227,
                "headline": "Wells Fargo Maintains Overweight on Johnson & Johnson, Raises Price Target to $272"
              },
              {
                "id": 140918830,
                "url": "https://finnhub.io/api/news?id=b8067d2e125f2fadd902082d475fcb21d24467c27a57848a9d67cfeb5786361c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Twenty thousand dollars a month in dividends means $240,000 a year that has to arrive whether the market cooperates or not. Reaching it is a math problem before it is a stock-picking problem, and the math gets uncomfortable fast when you compare that target with current yields. The core equation is unforgiving: annual income divided ... The Portfolio Blueprint for Building $20,000 a Month in Dividend Income",
                "category": "company",
                "datetime": 1784197760,
                "headline": "The Portfolio Blueprint for Building $20,000 a Month in Dividend Income"
              },
              {
                "id": 140925259,
                "url": "https://finnhub.io/api/news?id=8e8ff9972320acf9872e5c5f441d391a77a1bf0345ca3e918d5ba001518be010",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Morgan Stanley  analyst Terence Flynn   maintains Johnson & Johnson (NYSE:JNJ) with a Overweight and raises the price target from $284 to $294.",
                "category": "company",
                "datetime": 1784193945,
                "headline": "Morgan Stanley Maintains Overweight on Johnson & Johnson, Raises Price Target to $294"
              },
              {
                "id": 140925260,
                "url": "https://finnhub.io/api/news?id=014de1ad8e4e545a4a3f02e2d375594a5f01a2ee6dea5eaa486ec601be65e351",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "The transaction strengthens DePuy Synthes’ Spine portfolio and expands its position in the rapidly growing expandable interbody cage segment.Expanding Innovations (EI) is a commercial-stage medical technology company",
                "category": "company",
                "datetime": 1784189685,
                "headline": "Johnson & Johnson Unit DePuy Synthes Acquires Expanding Innovations, A Maker Of Expandable Implant Technology For Spinal Surgery; Financial Terms Not Disclosed"
              },
              {
                "id": 140918128,
                "url": "https://finnhub.io/api/news?id=f1402859602ca724ecf65893e4e4f5820ae506617dde2d10a6da383be625d1ad",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "J&J’s fast-growing Inlexzo bladder-cancer franchise could make IBRX either strategically attractive or a direct rival.",
                "category": "company",
                "datetime": 1784185971,
                "headline": "SLS, IBRX Rise Overnight: Retail Bets On Big Pharma Buyouts As J&J Chases No. 1 Oncology Spot"
              },
              {
                "id": 140916511,
                "url": "https://finnhub.io/api/news?id=e300002b4f43068403e89c192b53b22aa9c3919d052a002385f9017f92ad7e63",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Investors didn't seem to think so after the company published it.",
                "category": "company",
                "datetime": 1784173167,
                "headline": "Is Johnson & Johnson a Buy After Its Latest Earnings Report?"
              },
              {
                "id": 140925261,
                "url": "https://finnhub.io/api/news?id=9f5bb9cd16e73156160575776209683ad183e46e25dbce73d4396b83af3a0168",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/movers_2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) held its second-quarter earnings conference call on Wednesday. Below is the complete transcript from the call.\nThis transcript is brought to you by Benzinga APIs. For real-time access to",
                "category": "company",
                "datetime": 1784166947,
                "headline": "Full Transcript: Johnson & Johnson Q2 2026 Earnings Call"
              },
              {
                "id": 140915424,
                "url": "https://finnhub.io/api/news?id=ab8372ecfee687d7abf018b7dce66c686ad6cd08febf8c3946af69c275a4cd45",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "How do you find the best dividend stocks to buy? Income investors know there's no substitute for regular dividend increases over the long haul.",
                "category": "company",
                "datetime": 1784150433,
                "headline": "Best Dividend Stocks to Buy for Dependable Dividend Growth"
              },
              {
                "id": 140914231,
                "url": "https://finnhub.io/api/news?id=f0632b36b806d3d0cb47d42432e310a59cbd17a7770bb0e0c19a70aac93b683c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Wholesale inflation data cooled while major earnings season kicked off positively, lifting stocks across the board, today, July 15, 2026.",
                "category": "company",
                "datetime": 1784150173,
                "headline": "Stock Market Today, July 15: Markets Rise on Cooler Inflation and Strong Earnings Start"
              },
              {
                "id": 140914232,
                "url": "https://finnhub.io/api/news?id=895aec057b4e3597ccabce3d9f9e117a9483c72895b973727e2a43ca3def1bf1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (JNJ) reports robust sales growth and raises full-year guidance, despite facing headwinds from STELARA and challenges in the MedTech segment.",
                "category": "company",
                "datetime": 1784149262,
                "headline": "Johnson & Johnson (JNJ) Q2 2026 Earnings Call Highlights: Strong Sales Growth and Raised ..."
              },
              {
                "id": 140912812,
                "url": "https://finnhub.io/api/news?id=d1dbf1f7ea79f9594822717b2881011dd0b4feefcaa01d1669fa51610f4a8da0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Psychedelic drug developers including AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC), Compass Pathways (NASDAQ:CMPS) and Cybin Inc. (NYSE-A:CYBN, FRA:R7E) could see a positive read-through after Johnson & Johnson (NYSE:JNJ) reported stronger second-quarter sales for its Spravato depression...",
                "category": "company",
                "datetime": 1784144040,
                "headline": "Johnson & Johnson’s Spravato sales growth supports psychedelic drug opportunity: Jefferies"
              },
              {
                "id": 140912813,
                "url": "https://finnhub.io/api/news?id=af3b9436f23bb6328aa43e6b3e1faf8d7dd198364bfa6e28cf7cd911df9289f9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Intuitive Surgical's powerful growth is running headlong into some serious market challenges, and how management framed the collision tells you everything about the real risks.",
                "category": "company",
                "datetime": 1784140381,
                "headline": "The Open Questions On ISRG Stock"
              },
              {
                "id": 140911280,
                "url": "https://finnhub.io/api/news?id=20b0d88f50adb6770ced929f134ea877401a5f178c1c8488b3933a62a362de03",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Healthcare stocks rose Wednesday afternoon, with the NYSE Healthcare Index adding 0.4% and the State",
                "category": "company",
                "datetime": 1784137282,
                "headline": "Sector Update: Healthcare Stocks Advance in Afternoon Trading"
              },
              {
                "id": 140911186,
                "url": "https://finnhub.io/api/news?id=d2612052d9f84c92d994a744608379e467802d35adcdb495958f835110241182",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson and Johnson has quietly become one of the best-performing mega-caps of the past year, but with a fresh pullback and a pipeline firing on multiple cylinders, the bigger question is whether the next leg higher finally breaks through to record territory.",
                "category": "company",
                "datetime": 1784136544,
                "headline": "Prediction: This Dividend King Could End The Year With a New All-Time High Stock Price"
              },
              {
                "id": 140911295,
                "url": "https://finnhub.io/api/news?id=4a791776ab37db358676e8be6b305d1ec3123f5214f8c1346ecc26403cfddb47",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "PayPal stock leads the S&P 500 while Sandisk is among the worst performers. Micron falls as chip stocks book significant losses.",
                "category": "company",
                "datetime": 1784134800,
                "headline": "Micron, PayPal, IBM, SpaceX, BlackRock, and More Stocks That Explain Today’s Market"
              },
              {
                "id": 140911296,
                "url": "https://finnhub.io/api/news?id=aee602b293e01bdae62f2d6674938ab67845e74bf45b3536a1bd3aa55fdad064",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson stock dipped early Wednesday, though the healthcare giant beat second-quarter forecasts and raised its outlook.",
                "category": "company",
                "datetime": 1784134793,
                "headline": "J&J Slipped On Its Report; Why It Bodes Well For Intuitive, Abbott, Others"
              },
              {
                "id": 140910530,
                "url": "https://finnhub.io/api/news?id=d3f52428a05de534ed0291c48948492f6aadc30b433f1701d5322f7b8d1fb595",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Stay informed about the performance of the dow jones index in the middle of the day on Wednesday. Uncover the top gainers and losers in today's session for valuable insights.",
                "category": "company",
                "datetime": 1784133603,
                "headline": "Stay informed with the top movers within the dow jones index on Wednesday."
              },
              {
                "id": 140911297,
                "url": "https://finnhub.io/api/news?id=787e4c2e5b8b34dbaa7ba190f36e70608d9c07c20239be6b5eb232e1e3172fd9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson and Johnson just raised guidance while absorbing nine-figure litigation charges, and the stock is still near levels that have historically rewarded patient buyers. Whether the talc courtroom drama is drowning out a rare compounding opportunity depends on what the numbers actually say.",
                "category": "company",
                "datetime": 1784132843,
                "headline": "Stock Market Is Giving A Pristine Entry Point Into This 64-Year Dividend King"
              },
              {
                "id": 140912735,
                "url": "https://finnhub.io/api/news?id=8a8b81142b9c7e4bb5438d07823228179787f4ff25c9657eff00ab62eca89eb8",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Johnson & Johnson (JNJ) Q2 2026 Earnings Call July 15, 2026 8:30 AM EDTCompany ParticipantsRyan KoorsJoaquin Duato - CEO & ChairmanJoseph Wolk -...",
                "category": "company",
                "datetime": 1784131079,
                "headline": "Johnson & Johnson (JNJ) Q2 2026 Earnings Call Transcript"
              },
              {
                "id": 140909590,
                "url": "https://finnhub.io/api/news?id=88fcc255731ec69886d1295814f3e784ca3de4fa2badc7f414c8666b92de4cbb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "All three major US stock indexes were up in late-morning trading Wednesday, as technology stocks led",
                "category": "company",
                "datetime": 1784130649,
                "headline": "Top Midday Stories: PayPal Reportedly Gets Acquisition Offer From Stripe, Advent; ASML Misses Q2 EPS, Sales Estimates, Lifts Outlook"
              },
              {
                "id": 140909591,
                "url": "https://finnhub.io/api/news?id=7f9bf71fadecdd9a92d2d7c8741a7205f9c570edb10edb3efdbbed51786a82c2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson’s  second-quarter earnings were met with a shrug on Wall Street, but one of the drugmaker’s top executives insists the most powerful growth drivers are just starting to pick up speed.  J&J on Wednesday reported adjusted earnings of $2.90 a share, beating the $2.85 a share analysts had anticipated.  “I think the second quarter was just an affirmation of the first quarter,” Chief Financial Officer Joe Wolk said in an interview with Barron’s. “Our pharmaceutical unit continues to thrive, surpassing $16 billion in sales for the first time ever in the company’s history.”",
                "category": "company",
                "datetime": 1784128500,
                "headline": "Johnson & Johnson CFO Says This Drug Is Outperforming ‘Almost Any Launch’ in Recent Memory"
              },
              {
                "id": 140909592,
                "url": "https://finnhub.io/api/news?id=007d15c9cf8e2ff35d41bbed5ecbb0afd386fd8bd943e6f92ab6307e2cfd496b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Contributing around $8.9bn to its Q2 revenues of around $25.3bn, J&J MedTech’s performance was driven by its cardiovascular portfolio that includes the Shockwave IVL system.",
                "category": "company",
                "datetime": 1784128454,
                "headline": "J&J raises FY26 outlook following positive Q2"
              },
              {
                "id": 140909593,
                "url": "https://finnhub.io/api/news?id=d077f71ff7fbd751fd25832e105b62d8886c21a60d7ea11acb36a69a781e58a6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) has surpassed US$100b in annual revenue for the first time in its 140-year history. The milestone follows strong Q2 2026 results and an increase to full-year revenue guidance. Performance was primarily driven by the company’s Innovative Medicine and MedTech segments. For investors following Johnson & Johnson, this US$100b revenue milestone highlights the scale of its global healthcare footprint across pharmaceuticals and medical devices. The company operates...",
                "category": "company",
                "datetime": 1784128337,
                "headline": "Johnson & Johnson (JNJ) Tops $100 Billion In Annual Revenue For The First Time"
              },
              {
                "id": 140911298,
                "url": "https://finnhub.io/api/news?id=68daeb1521e8e1d59a5f8a5092dccf50dc34cd5e70838a036646bc5876a08361",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Producer Inflation Cools in June",
                "category": "company",
                "datetime": 1784127300,
                "headline": "Producer Inflation Cools in June"
              },
              {
                "id": 140909594,
                "url": "https://finnhub.io/api/news?id=ec340f83e790a33d8578eaabbe70e16e33fdc6e6b4e59590d771d0a8d3a886df",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "JNJ tops Q2 earnings and sales estimates, driven by key drug growth, and raises its 2026 outlook despite a slight MedTech sales miss.",
                "category": "company",
                "datetime": 1784127000,
                "headline": "J&J Q2 Earnings Beat on Darzalex, Tremfya Growth, 2026 Outlook Raised"
              },
              {
                "id": 140909595,
                "url": "https://finnhub.io/api/news?id=734ecd32e0b0bb076cabb9c846905c77fbf49fb3332c67befbe8f37a58387e50",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "ABBV stock rallies 9% YTD as Skyrizi and Rinvoq offset Humira declines, but can its pipeline, neuroscience growth and Apogee deal sustain long-term momentum?",
                "category": "company",
                "datetime": 1784126640,
                "headline": "Should You Buy, Sell or Hold ABBV Stock After Its 9% YTD Rise?"
              },
              {
                "id": 140909596,
                "url": "https://finnhub.io/api/news?id=ccd29988ec70f94492a68a9bfcc87fe887cf810dd56988d4d935a873da283740",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) reported better-than-expected second quarter results and raised its full-year 2026 outlook, as strong pharmaceutical sales helped offset headwinds from products facing patent competition. The healthcare company posted adjusted earnings per share of $2.90 for...",
                "category": "company",
                "datetime": 1784126520,
                "headline": "Johnson & Johnson beats Q2 estimates, raises full-year 2026 guidance"
              },
              {
                "id": 140909597,
                "url": "https://finnhub.io/api/news?id=d56e980eea938f5552ae174918377651845cf671b35640abd87fa2e22973148a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Year over year wholesale inflation pulls back to +5.5%, 100 bps lower than last month's initial print.",
                "category": "company",
                "datetime": 1784125920,
                "headline": "PPI Slides in June on Lower Oil Prices, Q2 Results Continue"
              },
              {
                "id": 140909598,
                "url": "https://finnhub.io/api/news?id=7dab795452149bd3414880bc74c107b79159251545e9f97ed6871bfed9ab6e77",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "FEATURE  Stocks were rising Wednesday, building on recent gains, as a cooler-than-expected producer price index print boosted investor sentiment. Wall Street also assessed another batch of quarterly earnings reports with chip-machine supplier ASML  offering an encouraging read on the artificial-intelligence trade.",
                "category": "company",
                "datetime": 1784125260,
                "headline": "Intel, Marvell, PayPal, IBM, and More Stocks That Explain Today’s Market"
              },
              {
                "id": 140909599,
                "url": "https://finnhub.io/api/news?id=02bc3408b143d0b0d2c85943c9e5093fa90ca7d4d087bd71c3ae77d3510fbd3e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) raised its full-year 2026 outlook after reporting second-quarter sales growth that management said was supported by strength in Innovative Medicine, new product launches and a broad portfolio that helped offset continued pressure from STELARA biosimilar competition.",
                "category": "company",
                "datetime": 1784124278,
                "headline": "Johnson & Johnson Q2 Earnings Call Highlights"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 2,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.6,
            "source_article_count": 241,
            "discarded_article_count": 222
          },
          "sentimentPoints": 4
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 18.2,
        "grade": "一般",
        "items": {
          "bbPoints": 2.4,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 0.9,
          "macdPoints": 2.4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 0.9,
            "vcp_reason": "站上MA50；升放量(近10日4日)；Ready=N；Confirm=N",
            "vcp_metrics": {
              "up_days": 7,
              "vol_ref": 8963410,
              "down_days": 2,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 8693290,
              "avg_vol_20": 8083090,
              "avg_vol_30": 8963410,
              "range_pct_10": 0.11496356363992008,
              "range_pct_20": 0.11496356363992008,
              "range_pct_30": 0.18528648325828775,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": false,
              "down_shrink_ok": false,
              "up_expand_days": 4,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.9698641476848655,
              "dist_to_20d_high": 0.06940698688275691,
              "down_shrink_days": 2,
              "breakout_level_20d": 274.89999,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.6204638439797137
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0.8,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0.6,
          "volumePointsTechnical": 0.8
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "良好",
        "items": {
          "position": {
            "score": 1.8,
            "details": {
              "atrPct": 2.5673519440484736,
              "turnoverUsdM": 1703.82829144262,
              "liquidityPoints": 0.8,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.JNJ",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 242.6844,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 2,
              "rsi_score": 1,
              "macd_score": 1.5,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1,
            "stop_loss_percent": 5.1,
            "take_profit_price": 268.611,
            "target_multiplier": 1.6,
            "technical_strength": 1.38,
            "take_profit_percent": 5
          },
          "positionPoints": 1.8,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 5.134703888096947,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 85.71,
    "atr": {
      "atr": 6.5678,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.57
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "弱勢",
      "score": 4,
      "value": -18.55
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "派發",
      "score": 2,
      "value": -0.0974
    },
    "kdj": {
      "d": 64.58,
      "j": 51.07,
      "k": 60.08,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "弱流入",
      "score": 4,
      "value": 46.23
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 10,
      "trend": "強流入",
      "value": 60844638,
      "recentSlope": 3056673.8,
      "previousSlope": -1022460
    },
    "rsi": 48.85,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 250.0463,
      "position": "SAR喺價下",
      "distancePct": 2.26,
      "previousTrend": "上升"
    },
    "ma50": 244.6744,
    "macd": {
      "macd": 4.590467718752166,
      "trend": "中性偏多",
      "signal": 4.7253131930765395,
      "histogram": -0.13484547432437388
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 2,
      "value": 258.0576,
      "position": "<VWAP",
      "consecutiveAbove": 0
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "無力",
      "ratio": 0.82,
      "score": 4,
      "avgVolume": 8090278,
      "currentVolume": 6660262
    },
    "derived": {
      "ma20": 258.125,
      "ma50": 244.6744,
      "prevClose": 265.53,
      "avgVolume10": 8249556,
      "avgVolume20": 8090278,
      "changePercent": -3.66,
      "avgVolumeForScore": 8090278
    },
    "ma_cross": {
      "ma20": 258.125,
      "ma50": 244.6744,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 258.033,
      "prevMa50": 244.1364,
      "spreadPct": 5.5,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 245.9045,
      "upper": 270.3455,
      "position": "中間"
    },
    "rsi_short": 50.43,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.82
    }
  }
}

{
  "close": 255.82,
  "volume": 6660262,
  "changePercent": -3.66
}